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Abstract 
The Medicare Hospice Benefit (MHB) provides terminally ill Medicare beneficiaries 
with a program of care specifically targeted to shifting the goals of medical care from 
curative to palliative care.  The American Society of Clinical Oncologists (ASCO) 
considers hospice to be the optimal system of care for patients with cancer who are dying.   
This research evaluates use of the MHB among patients with cancer using the 
Surveillance, Epidemiology and End Results (SEER)-Medicare linked database.  We use 
novel methodologies and data fields which have only recently become available to 
understand whether these patients are using the MHB as expected given its design.   
The Peters-Belson method is used to understand the disparity in hospice use between 
blacks and whites over time in patients with terminal cancer diagnoses (pancreatic, lung 
and advanced gastric cancers). We find that while use of hospice has grown for both 
groups, the observed disparity has increased from 1992 to 2008 while the difference 
between the observed and expected disparity (based on differences in population factors 
between the groups) has increased over time from <-1% to 33%.   
We also find that patients with lung cancer who use no cancer directed treatment use 
hospice at the same rate as patients who use three or more cancer directed treatments 
(adjusted odds ratio (OR) of 0.892 (95% CI: 0.775-1.026)).  Patients who use two or 
more treatments are significantly less likely than patients with three or more treatments to 
use hospice (OR=0.838, 95% CI: 0.728-0.965).   
Finally, we find that 30% of hospice patients with cancer do not die at home, despite 
the home-based design of the benefit.  Almost half of hospice users who died in the 
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hospital had a total length of stay of 3 days or fewer, and two-thirds had a length of stay 
less than 1 week, suggesting a shift to the hospice payment system without time to benefit 
from the system of care. 
Our results demonstrate the continuing importance of monitoring and investigating 
disparities in hospice use, expanding access to palliative care for patients who use cancer 
directed treatment, and reforming payment incentives for hospice care provided in 
institutions. 
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Introduction 
 
Hospice is a program of health care used at the end of life that involves a shift in 
treatment focus from curative care to pain and symptom management. The American 
Society of Clinical Oncology has identified hospice as the best system of care for patients 
who are dying,1 and because hospice is associated with positive outcomes for both 
patients and bereaved family members,2,3 use of hospice is often used as an indicator of 
quality of care at the end of life.4 Medicare has covered hospice care since 1983. Use has 
grown tremendously in the last two decades; almost half (45.2%) of Medicare 
beneficiaries who died in 2011, over 1 million people, used hospice.5  
Hospice is most helpful to the patient when initiated more than one week prior to 
death4,6 and many argue for an even longer time frame to benefit.7,8 Timely referral to 
hospice is easier when the prognosis is more certain.9 Patients dying of cancer have a 
relatively predictable decline prior to death making the recognition of the end of life more 
obvious.10 Hospice was, in part, designed for patients with cancer and their families who 
needed pain and symptom management and emotional and spiritual support as they faced 
death but wished for care outside of a medical institution.11 The arsenal of treatments for 
cancer is constantly growing.12–15  To access the Medicare Hospice Benefit (MHB), 
however, patients must discontinue use of curative or life extending treatment.16  
Most discussions of the use of hospice implicitly contain three assumptions about 
hospice based on the facts above.  First, the assumption that increased use in recent years 
signals the availability of the benefit to any who wish to access it.  Second, an assumption 
that hospice is a substitute for aggressive care because patients must stop receiving 
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reimbursement for aggressive care when they enroll in hospice.  Third, because the MHB 
was designed to be a home-based benefit, the assumption that death in hospice means that 
the death occurred at home.  This dissertation will examine these assumptions in three 
analyses answering the following questions: 
(1) Has the disparity in rates of hospice use between blacks and whites lessened over 
time with increased access to hospice? 
(2) Does receipt of aggressive cancer treatment affect use of hospice? 
(3) Where do hospice patients die? 
By understanding the empirical data regarding these assumptions, hospice 
advocates and policymakers will have a greater understanding of how the MHB is 
currently being used and where improvements are needed. 
Background and Motivation 
The Medicare Hospice Benefit 
The MHB was created in 1982 to provide all Medicare beneficiaries who have a 
life expectancy of six months or less financial access to hospice programs.17  The hospice 
program is required to provide nursing and home health aide services, drugs for pain and 
symptom control, and counseling, and may provide physical, occupational, and speech 
therapy, and other services.16   The MHB is available to beneficiaries enrolled in either 
managed care (HMO) or fee-for-service (FFS) Medicare; for those enrolled in managed 
care, it is a “carve-out” benefit—payment comes from CMS rather than from the 
managed care company.  Patients may not receive Medicare reimbursement for treatment 
aimed at curing their terminal condition, but they may receive Medicare reimbursement 
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for treatment of unrelated conditions.18  For example, a person with lung cancer who is 
being treated for diabetes must relinquish reimbursement for lung cancer treatment but 
can continue to receive reimbursement for diabetes care. Medicare is the primary payer 
for almost 80% of hospice discharges.19 
Medicare pays hospices on a per-diem basis; the payment rate depends on the 
level of care provided each day.  Almost 97% of paid days are ‘routine home care’ 
(RHC).5  Under this payment rate, the patient usually resides at home and is expected to 
have a caregiver, usually informal such as a friend of family member. A hospice staff 
member visits to provide care, and the per diem rate is billed for every day the patient is 
enrolled in hospice, regardless if a visit is made on that day.  If the patient is in crisis and 
requires more attention from hospice staff but remains where they reside, the day is billed 
at the ‘continuous home care’ rate.  If the patient’s primary informal caregiver needs a 
break, the patient may be admitted to an inpatient facility and the days are billed as 
inpatient respite care.  Finally, if there are symptoms for which management requires 
inpatient care, the care is billed at the general inpatient care rate (GIC).   The hospice 
covers all services provided out of the per diem payments collected.5,18 
Hospice use is associated with improved quality of life for patients and families of 
patients.  Hospice staff specialize in symptom management for dying patients, which 
results in improvements over other care models.2,3  Psychosocial and spiritual care for 
both the patient and their family members leads to greater satisfaction and aids the 
bereavement process.3,20,21  Some say the greatest benefit to hospice users is the 
acceptance that death will occur soon which provides the chance to get “affairs in order” 
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and take the time to say goodbye to loved ones, a process facilitated by the hospice.22  In 
surveys of how people wish to die, the majority of people respond “at home” and 
“surrounded by loved ones,” situations promoted by hospice and not by traditional 
institutional care.23–25  Yet the rate of patients with terminal conditions enrolling in 
hospice is lower than expected, based on these benefits. 
Most Medicare beneficiaries have, at minimum, financial access to hospice.  The 
MHB is available to all persons enrolled in Part A (Hospital Insurance) and requires no 
additional costs beyond eligibility.  The MHB has historically been one of the most 
generous Medicare programs for patients, requiring very minimal copayments and 
including payment for drugs.  While not all persons who die could benefit from hospice 
(because a death may be unexpected), it is generally accepted that many more patients are 
eligible for hospice than choose to use the benefit. A recent study of deaths in one 
hospital found that 60% of patients who had been admitted at least once before in the 
previous year where hospice eligible at the time of the penultimate admission.26 This 
could indicate lack of access to hospice, patient preference or lack of knowledge of 
hospice eligibility.  In the previously described study, only 14% of the hospice eligible 
patients had documentation of a discussion about hospice.26  Yet reported preferences of 
most patients for the end of life include good pain management, presence of family and 
friends, a familiar environment and avoidance of technology intensive hospitalizations27--
all of which occur more often in hospice.   
Barriers to access to hospice care include: certification of a life expectancy of less 
than 6 months, willingness to forgo life extending treatment while under hospice care, 
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access to informal caregiver(s) to care for the patient at home, and having hospice 
services available geographically.28,29  These barriers result in subpopulations of patients 
who are less likely to receive care based on non-medical factors. 
Variation in use of hospice 
African American and Latino patients have significantly lower rates of hospice 
use than European Americans.30,31 Some conjecture a general preference for aggressive 
rather than curative treatment at the end of life among cultural groups;32 while the 
majority of Americans would prefer to die at home, subgroup analysis in one study found 
that 62% of African Americans would prefer to die in a hospital.33 It is noteworthy that 
while hospice diffused across the population in the 1990s and reduced the variation in 
hospice users, the disparity between blacks and whites was largely unaffected.34 
However, other factors may also play a role in the disparities: mistrust of the health care 
system, lack of knowledge of end of life care options (possibly due to the poor quality of 
care, as discussed above),35 or lack of access to care.36.  
 There are also documented geographic differences in hospice use, which could 
stem from health system differences, cultural differences or both. Hospice use has been 
found to be higher in the South and Southwestern US and lower in the Midwest and 
Northeast. State rates of hospice use prior to death varied from 8% to 49%.37  Virnig et 
al.38 found that in 1996, rates of hospice use in large metropolitan statistical areas 
(MSAs) varied from 35.15 to 397.2 per 1000 deaths.  Persons living in wealthier areas 
and in urban areas also had significantly higher rates of hospice use than their less 
wealthy and rural counterparts, respectively.  Hospice use was positively related to 
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average reimbursements for health care and physicians per capita38 and unassociated with 
reported patient preference for aggressive treatment differences in geographic areas.39 
 Other health system characteristics, such as enrollment in FFS Medicare versus 
Medicare HMO are important despite geographic location.40,41 Physician incentives 
within HMO settings are consistent with increased use of hospice and with fewer patients 
experiencing very short lengths of stay in hospice.42  Patient factors interact with the 
payment system in varied ways as well.  Income impacts hospice use differently in HMO 
or FFS Medicare, while other factors, such as race, impact hospice use in much the same 
way regardless of insurance type.43 
 Quality care at the end of life consists not only of enrolling in hospice prior to 
death but also of using it for long enough to achieve benefit.4  The length of time a person 
lives after enrollment in hospice has been found to vary by patient and hospice 
characteristics.  Male sex, white race, and disease burden are associated with shorter 
survival after hospice entry.44  Enrollment in FFS Medicare or a Medicare HMO impact 
length of stay in hospice as well.40,42  Characteristics of hospices, such as for-profit status, 
large size, and being newer are also associated with shorter enrollment periods.45   
 Variation in use, length of stay, and cost savings at the end of life are the most 
common lines of inquiry for studies of hospice.  Relatively little attention has been paid 
to the care received prior to hospice entry or death, including the care surrounding the 
terminal diagnosis.  Yet when patients are asked to forgo further treatment for their 
terminal condition in order to enroll in hospice, one might expect that the diagnosis 
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experience itself and the care received might have impact on that choice.  Variations in 
cancer diagnosis and treatment are also widely documented. 
Variation in cancer diagnosis and treatment 
Variation in cancer care can be seen early in the course of medical care impacting 
timing of diagnosis.  Disparities in screening and general access to medical care result in 
disease that is more serious upon diagnosis. For cancers for which screening is available, 
participation in screening varies by race and ethnicity, age, sex, and measures of 
socioeconomic status (SES) such as years of education, health insurance status, and 
poverty.46,47  Singh et al47 found that for female breast cancer, cervical cancer, prostate 
cancer, and colorectal cancer, the proportion of African Americans, Hispanics/Latinos 
and American Indians/Alaskan Natives diagnosed with regional or distant disease is 
significantly higher than for Whites and Asian Americans/Pacific Islanders.  Disparities 
in stage at diagnosis by race and SES (area poverty rate) are also found in cancers for 
which screening is not available, such as lung cancer.46,47  
Differences in mortality rates for cancer are also well documented but cannot be 
completely attributed to late discovery of the disease.  Disparities in diagnostic evaluation 
after diagnosis also occur, and this is important because diagnostic evaluation provides 
information about the extent of disease, which will determine the most appropriate initial 
course of treatment.  For example, after diagnosis of cervical cancer, African American 
women are more likely than white women to remain unstaged and receive no treatment.48    
Studies of cancer treatment among races have found that outcomes of a treatment 
are similar if patients receive the same treatments and supportive care; however, in the 
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general population, stage-specific survival is not equal among races.  While there is 
evidence for increased survival with chemotherapy treatment for ovarian cancer among 
all races, rates of use are lower for black patients.49  Rates of recommended treatment for 
early stage non-small cell lung cancer differ by race, even after controlling for income 
and insurance coverage.50  
In summary, the contribution of non-medical factors to the diagnosis and 
treatment of cancer impacts outcomes for patients.  Patients who do not receive 
recommended care may be less likely to enter remission from cancer, have cancer recur 
sooner, and/or die from the cancer sooner.  Variations in quality of care at one point in 
time of the illness will impact future events for the patient. 
The factors influencing care at diagnosis are the remarkably similar to those found 
to influence the use of hospice (Table 1).  While cancer causes a relatively predictable 
period of decline prior to death, hospice participation could not conceivably reach 100 
percent among cancer patients.  Death may come suddenly due to complications of 
treatment or other causes unrelated to the cancer. Also, some patients may prefer not to 
enroll in hospice so that they can pursue cure or life extension or they may prefer a non-
hospice setting for death.  Similarly, patients may have differing treatment preferences 
for cancer care.  However, the variations in hospice use and cancer care seen from the 
population-level are systematic and do not suggest that personal preference alone can 
explain these subgroup variations.   
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Initial workup/treatment Hospice care 
Age 
As age increases, 
aggressiveness of care 
decreases 51,52 
As age increases, use of 
hospice care decreases31 
Sex Women tend to have less aggressive care 53,54 
Women tend to use 
hospice less55 
Race/Ethnicity 
African American women 
more likely to remain 
unstaged after diagnosis48 
Lower use among African 
Americans and Latinos 50 
Lower use among African 
Americans and Latinos30,31 
Insurance 
Earlier stage at diagnosis and 
increased use of adjuvant 
therapy in Medicare HMO56  
Medicare HMO patients 
use hospice at a higher rate 
than FFS patients 40,42 
Time 
Increased use of 
chemotherapy/radiation in 
initial treatment 57 
Increased use of hospice 
over time 58,59 
 
Research plan 
With this background in mind, I propose a conceptual model that incorporates 
both hospice and other treatment options available to patients with a cancer diagnosis 
(Figure 1).  Patient sociodemographic characteristics influence the cancer diagnosis as 
well as access to and preferences for both curative treatment and all aspects of hospice 
use (use, length of use and place of death).  Whether curative treatment is used 
determines use of hospice including how long hospice is used and where it is used.  This 
conceptual model forms the basis of the three studies of hospice care, each of which is 
discussed in detail in the following pages. 
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Figure 1.  Conceptual model 
 
 








Assumptions about hospice 
Access 
Since the inception of the MHB, the numbers of patients using hospice prior to 
death has grown dramatically.  During the same period, the percentage of people using 
hospice for less than one week prior to death has increased, meaning that some are using 
hospice as a “place” to die rather than a means of care prior to death.   This is concerning 
because the benefit of hospice as an interdisciplinary care team providing physical, 
emotional, and social support prior to death is minimized when the patient enters hospice 
only after he or she is actively dying.  Although use of hospice prior to death and length 
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trends over time show improvement in use of hospice but decline in optimal length of 
stay (i.e., more than 7 days but less than 180 days). 
Despite increasing hospice use among all races as the number of hospices has 
grown, a significant disparity in use of hospice prior to death remains between non-
Hispanic blacks and non-Hispanic whites in the Medicare population.60   Some studies of 
length of stay in hospice, including internal analyses, have found that median length of 
stay of non-Hispanic blacks and Hispanics in hospice is similar to if not greater than the 
median length of stay of non-Hispanic whites.40,58   
There have been no studies to my knowledge examining trends in the use of 
hospice for what is considered an optimal amount of time (more than 7 days but less than 
180 days).  Lengths of stay of less than 7 days has been considered a “short” hospice stay 
in the literature since the 1990s,9,45,61although a few have suggested that three days would 
more appropriately describe a stay too short to benefit the patient.4  Stays greater than 
180 days are considered “long use,” and again question the benefit of highly specialized 
care for the dying patient when the patient instead lives so long that they may have 
achieved greater benefit from rehabilitative care.9  A length of stay of 180 days also 
coincides with the end of the second ninety day hospice benefit period, after which 
patients need to be recertified as eligible for the benefit every 60 days.16 
Our first analyses will focus on whether the disparity in hospice use between 
whites and blacks has changed over time and how differences between the populations in 
factors associated with hospice use, such as age at diagnosis, geographic location, sex, 
marital status, income and Medicare payment system explain hospice use over time.  
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Both overall use of hospice and optimal use of hospice will be measured due to the trend 
in a decreasing proportion of optimal use among hospice users.59 
Preference for less aggressive treatment 
Those who use hospice are generally believed to have a preference for less 
aggressive treatment.62,63 As described by Beeuwkes-Buntin and Huskamp:29 “there is 
likely to be selection bias associated with the use of hospice:  Individuals who choose 
hospice are less likely to have pursued aggressive intervention even if hospice was not an 
option” (p.42).  Cost studies of hospice have shown this not to be the case: prior to 
entering hospice, hospice users do not appear to have a preference for less aggressive 
care.  “However, some researchers did not find hospice enrollees to have a lower 
propensity for hospitalization, at least before hospice enrollment; they found in Months 2 
through 6 before death (before hospice enrollment for most dying in hospice care) that 
average healthcare costs were significantly higher for hospice versus nonhospice 
decedents”.64 “Evidence from the evaluation suggests that [Medicare Hospice] benefit 
enrollees were terminally ill and heavy users of health services longer than the average 
non-benefit patient”.65  While patients enrolled in the hospice benefit necessarily use 
fewer resources for their terminal condition once enrolled, due to the benefit’s design, 
this analysis questions whether the amount of curative of life extending treatment 
received is associated with hospice use.  
Studies seeking to understand who chooses to use hospice have focused almost 
exclusively on the time period immediately prior to death, examining associations 
between demographic, socioeconomic, geographic, and market factors and use of hospice 
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prior to death.  However, a large experimental study (Study to Understand Prognoses and 
Preferences for Outcomes and Risks of Treatment (SUPPORT)) and anthropological 
studies observing care of seriously ill patients, have given evidence against the notion of 
a single decision to discontinue life extending treatment at the end of life.66  Instead, they 
argue for “pathways” of treatment: the absence of discrete decisions in favor of “usual 
next steps.”66–68  A pathway is comprised of a series of medical treatments or tests over 
time, with each step depending upon the outcome of the last.  Diagnostic and treatment 
algorithms, based on evidence, exist to inform the next step and become the routine—
once on the pathway, it becomes difficult to deviate from the routine.   When the first 
treatment fails, the next is tried.  It becomes difficult to inset the hospice “choice” before 
all existing treatments have been tried.  If this is the case, we hypothesize in our second 
paper that we will observe more hospice use with more treatment. 
Home death 
The early hospice movement and the MHB focused on moving end-of-life care 
out of institutions and into the home.  The placement of the MHB in the Tax Equity and 
Fiscal Responsibility Act of 1982 (TEFRA)17 is indicative of the hope for the benefit—to 
shift costs from the Federal government back to families.  One piece of this is increasing 
the reliance on informal caregivers, usually friends and family members.  The benefit’s 
capitated design and explicit caps on the number of inpatient days allowed would lead 
one to expect that most deaths occur in the patient’s home.  Yet the increase in very short 
stays in hospice may make it unlikely that patients have time to transition to home if they 
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received care in an institution, and the increase in use of hospice in nursing homes make 
these likely places for hospice death as well. 
 Several single institution and single system studies have suggested that many 
patients do not die at home.69–71  New information on location of service in the Medicare 
administrative data allow us to assess national trends in place of death for elderly patients 
with cancer who used hospice.  Our third analysis will examine the relationship of 
demographic factors such as age, race, geographic location, marital status, Medicare 
payment system to understand factors associated with place of death among hospice 
users. 
Data 
Our study used SEER-Medicare linked data, which provides a unique opportunity 
to study this topic. The SEER (Surveillance, Epidemiology and End-Results) Program is 
a collection of population based tumor registries headed by the National Cancer Institute. 
The database ensures that data are collected so that they can be compared across regions.  
SEER data from some registries are available since 1973.  With the addition of four 
registries in 2000, there are a total of 16 SEER areas, representing 25% of the United 
States population of cancer patients, which share common reporting standards so that 
data can be pooled.72  Patients with cancer are of interest in end-of-life care because of 
the more predictable prognosis associated with the disease.73   SEER data are linked with 
Medicare claims data using patient identifiers and, after identifiers are removed, are made 
available for a fee. 
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Contained within the SEER data are: date of diagnosis, stage and grade at 
diagnosis, histology of the tumor, surgical or radiation treatment recommended or 
provided within 4 months of diagnosis, follow-up on vital statistics, cause of death, and 
patient demographic characteristics. Linkage with Medicare administrative data provides 
opportunity for longitudinal study designs.  These data include information on the use of 
health services. The linkage of these databases allows analysis of health care utilization 
before and after diagnosis and prior to death, and provides key information about the 
stage and grade of the cancer at diagnosis and treatment recommended at the time of 
diagnosis.74  
Linkage with the Medicare database limits the population to those 65 and over 
and those who qualify for Medicare due to disability; however, because the disabled 
population is so different from the general population, analyses using these data are often 
limited to those over 65.  The benefit of this population is that it is population that is 
universally insured, reducing (though not eliminating) financial barriers to medical care.  
We identified patients diagnosed with lung, gastric and pancreatic cancer between 
the years 2000 and 2005 from the Patient Entitlement and Diagnosis Summary Files 
(PEDSF) of the SEER-Medicare linkage.  These cancers were chosen because of the 
relatively short survival associated with diagnosis at almost any stage.  This increases the 
chances of observing diagnosis and death from the cancer within the same time period.  
Three cancers were chosen to assess the variability across cancers and to increase the 
sample size, particularly among the minority subgroups.  
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Medicare data provide longitudinal healthcare utilization information and were 
used to determine hospice use prior to date of death.  The population was limited to non-
Hispanic white, non-Hispanic black, and Hispanic patients who were diagnosed with 
cancer after the age of 65 and died as a result of cancer within the follow-up period.  
Patients were required to have been enrolled in Medicare Parts A and B from diagnosis 
until death.  The cohort was limited to patients for whom this is their first and only 
cancer. Registries with very low numbers of non-Hispanic black and Hispanic patients 
during the study period were excluded from our analysis.  Other races were not included 
due to very low numbers in most registries.  Patients with an unknown month of 
diagnosis in the SEER registry were excluded from our analysis because it eliminates the 
possibility of survival analysis. 
 Medicare data include information on hospice use in the Hospice Standard 
Analytic File (SAF). Patients were considered to have used hospice if there was a hospice 
claim in prior to death.  The date of death is identified in the database as the date reported 
to the Healthcare Financing Administration (HCFA) from the Social Security 
Administration (SS).  Date of death was identified in SEER as well—the level of 
agreement between SEER and Medicare is generally high and was reported.   
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The Medicare Hospice Benefit (MHB) was enacted in the early 1980s, and the 
number of patients using hospice prior to death has continued to grow dramatically. 
Approximately 23% of Medicare decedents in 2000 and 43% of Medicare decedents 
(over 1 million users) in 2010 used hospice.75  However, many terminally ill people do 
not take advantage of the MHB, and previous studies have reported that patients’ clinical 
and demographic characteristics are associated with hospice use. Rates of hospice use 
vary by race, with blacks using hospice less than whites.  Patients with lower income and 
educational attainment,30,38,41 single people,76  patients enrolled in fee-for-service 
payment plans (vs. managed care),41 and patients residing in rural areas have also been 
found to have lower rates of hospice use.38,77 Many of the aforementioned factors are also 
correlated with minority status, such as lower income and greater likelihood of being 
unmarried, which adds complexity to understanding the association of race alone.58,78  
Some of the increase in hospice use is likely due to the diffusion of hospice 
throughout the population.34  As the availability and marketing of hospice has increased, 
this may have led to changes in awareness and acceptance of palliative versus aggressive 
treatment at the end of life.  Also, the hospice setting has changed over time.  Hospice is 
increasingly being provided in settings other than in the patient’s home (e.g., inpatient 
hospices and nursing homes) so patients without family caregivers may take advantage of 
the benefit.  These changes may have led to a decrease in the disparity associated with 
income, payment type, population density, and marital status.34  
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Part of the increase may be a technical increase in use without much benefit to 
patients. The proportion of hospice users with very short stays in hospice, whereby a 
person enrolls less than one week prior to death, has increased over time from 16% in 
19906 to 31% in 2007.79 This is concerning because the benefit of hospice is diminished 
when the patient enters hospice only after death is known to be imminent.9 Stays greater 
than 180 days are considered “long use,” and again question the benefit of highly 
specialized care for the dying patient when the patient instead lives so long that they may 
have achieved greater benefit from rehabilitative care.9  Patients with cancer, particularly 
cancers with poor prognoses, are less likely to use hospice for greater than 180 days than 
patients with noncancer diagnoses, which have a less predictable decline towards death.80 
Despite overall increases in hospice use, black patients are consistently found to 
have significantly lower rates of hospice use than white Americans.31,36,58,78,81  In general, 
despite lower hospice use, when black cancer patients are enrolled in hospice, they have 
longer median length of stay than white patients and are less likely to stay less than 7 
days.40,58,82  
 Patients with cancer are the prototypical hospice patient and have a relatively 
predictable decline toward death.10 Gastric, lung, and pancreatic cancers are associated 
with poor survival with few effective treatments.  Thus, many of these patients are 
hospice candidates at diagnosis.83  In our study, we use the Peters-Belson (PB) method to 
unpack the interaction between race and other factors associated with hospice use over 
time for this population of known terminal patients.  To account for the increase in use 
attributable to people entering hospice immediately prior to death, we also examine 
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“quality hospice use,” defined as stays between 7 and 180 days, to better understand the 
previous finding that while blacks use hospice less frequently than whites, they are more 
likely to have a longer stay in hospice.  Using the PB method, we are able to calculate 
predicted rates of hospice use and quality hospice use for the black population and add to 
the current literature documenting disparities in hospice use by estimating the unadjusted 
rates and predicated rates of hospice use by blacks and non-Hispanic whites over time. 
Methods 
Data 
Data from the Surveillance, Epidemiology and End Results (SEER)-Medicare 
linked database were used to study patients diagnosed with cancer between 1992 and 
2007 who subsequently died due to cancer between 1992 and 2008.  This database is 
available from the National Cancer Institute (NCI) and includes information on all 
incident cases of cancer diagnoses within the geographic areas of the United States that 
participate in the SEER program.   Medicare claims are linked to the SEER cancer 
information, providing a longitudinal database.  This analysis includes patients who 
resided in the SEER areas that have continuously participated in the program since 1992 
and have adequate representation of blacks (at least 5% of the cancer cases)-San 
Francisco, Connecticut, Detroit, New Mexico, Seattle, Atlanta, San Jose, and Los 
Angeles.   
Population 
The study population included non-Hispanic white and black patients aged 65 and 
older who were diagnosed with regional or distant lung or gastric cancers, or any stage 
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pancreatic cancer and who died as a result of cancer within the follow-up period.  These 
cancers were chosen because of the relatively short average survival associated with their 
diagnosis.  To observe hospice use after diagnosis, patients were required to have been 
enrolled in Medicare Parts A and B from diagnosis until death.  Because the MHB is 
billed to CMS, even for managed care patients, patients enrolled in Medicare managed 
care were included.  The cohort is also limited to patients for whom this was the first and 
only cancer.  We excluded patients with an unknown month of diagnosis in the SEER 
registry and patients who enrolled in hospice prior to the observation period.  A figure 
with exclusions can be found in the appendix.  The cohort included men and women with 
a first primary diagnosis of pancreatic (n=16,955), lung (n=74,979), and gastric 
(n=7,156) cancer.   
Measures 
Death in hospice was defined as a hospice claim indicating a discharge status of 
‘expired’ or in which the date of discharge from hospice matches the Medicare date of 
death. Patients with a discharge status of ‘expired’ whose Medicare date of death differs 
by more than 3 days from date of hospice discharge were excluded from the analysis 
(n=141).  Length of stay in hospice was measured from date of hospice enrollment until 
discharge.  Quality hospice stays were defined as stays greater than 7 days and less than 
180 days.  If someone is discharged from hospice alive, we do include this as a quality 
stay because our main focus is earlier enrollment in hospice. 
We obtained patient’s race, and tumor stage (localized, regional, distant) and 
cause of death from the SEER data.  We obtained marital status, sex, age at death, length 
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of survival after diagnosis, and health maintenance organization (HMO) enrollment 
(defined as enrollment in HMO during month of death) from Medicare data.  Zip code 
level education (% of population over 25 in zip code with more than high school 
education) and zip code level median household income were obtained from the SEER-
Medicare linkage, which are linked from the 2000 United States Census.   
Statistical analysis 
  Unadjusted rates of hospice use over time for blacks and non-Hispanic whites 
were examined.  Unadjusted rates of hospice and quality hospice use over time for both 
groups were evaluated using the Cochrane-Armitage test for trend.  Differences in rates 
of hospice use by race during each time period were assessed using the chi-square 
statistic.  Median length of stay was calculated for each year of the time period for both 
race groups. 
The Peters-Belson (PB) method, 7-9 also known as Blinder-Oaxaca method in 
econometrics, 10-12  has most often been used to understand racial disparities in wages and 
hiring decisions,13 but has also been recently used to understand racial disparities in 
receipt of health services.14  In our case, the method involves using multivariate logistic 
regression to model hospice use among non-Hispanic whites using factors known to be 
associated with hospice use from previous studies and applying estimates obtained from 
that model to generate predicted probabilities of hospice use among blacks.  The 
measure, in essence, describes the magnitude of the disparity among races that cannot be 
explained by the factors we have included in the model.   
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 We used the PB method in models predicting hospice use by adjusting for 
demographic (socioeconomic characteristics of zip code of residence, marital status, age, 
geographic location, sex, HMO enrollment) and disease factors (stage at diagnosis, 
survival) which may also account for differential use of hospice among subgroups.  Due 
to our inclusion of patients enrolled in HMO (for whom claims are not available), we are 
unable to adjust for other case-mix differences.  First, we calculated unadjusted rates of 
hospice use over four year time periods (pooling due to small numbers) from 1992-2008 
for blacks and non-Hispanic whites.  Next, we fit a logistic regression model estimating 
association of hospice use among non-Hispanic whites and the following variable: age, 
sex, area income and educational attainment, marital status, enrollment in fee-for-service 
payment plans (vs. managed care), cancer diagnoses and geographic location.  We 
applied these individual fitted values from whites to blacks to predict how hospice use 
would differ among black patients if they were white.  The model was run for four time 
periods 1992-1995, 1996-1999, 2000-2003 and 2004-2008 to assess how the association 
of race with hospice use changed over time. Standard errors and confidence intervals of 
the model contribution were calculated using the delta method.15 
We performed additional analyses to ensure that our conclusions were not 
sensitive to the choice of years or the exclusion of registries without adequate 
representation of all groups of interest. 
Results 
The distribution of members of the black and non-Hispanic white groups differs 
across most of the demographic factors associated with hospice use (Table 1).  Blacks are 
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younger and are much less likely to be married, and live in zip codes with lower 
educational attainment and income than non-Hispanic whites in all time periods.   
There were significant increases in hospice use from 1992-2008 for both non-
Hispanic whites (1992-1995: 36.5% to 2004-2008: 65.5%; p<.001) and blacks (1992-
1995: 30.8% to 2004-2008: 57.3%, p<0.001) (see Figure 1).  However, these increases 
did not result in a decrease in disparity in hospice use, which actually increased from 
4.9% to 8.7% (see Table 2).   
 Figure 1b displays significant increases in quality hospice use from 1992-2008 for 
non-Hispanic whites (1992-1995: 24.7% to 2004-2008: 40.2%) and blacks (1992-1995: 
20.2% to 2004-2008: 35.5%; all trend tests significant at p<0.001); however, the increase 
is smaller than that for any hospice use.  The disparity in quality hospice use between 
blacks and non-Hispanic whites remains significant over time between 4.0 and 5.3%.  
Most patients who experienced a stay in hospice but did not experience a quality stay in 
hospice had a stay of less than 7 days (75%; data not shown in table). 
Adjusted comparisons between groups require adequate overlap among groups for 
each of the factors. Table 1 displays the differences between groups and demonstrates 
that there is adequate representation of each group in the levels of each factor.   
 Results from the PB analysis of black and non-Hispanic white hospice use are 
displayed in Table 2.  While disparities in hospice use were similar between the 1992-
1995 and 2004-2008 time periods (4.9% and 8.7%, respectively), the amount of the 
disparity explained by the clinical and other demographic characteristics in the base 
model differed between periods.  In the earlier period, 105% of the disparity was 
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explained by differences in other (non-race) model factors (meaning that if blacks 
retained all of their characteristics but were white their overall rate of hospice use would 
be smaller than observed). In the later period, 63.4% of the disparity was explained by the 
model meaning that 36.6% of the disparity in hospice use was unexplained by model 
factors.  The results contrast to those for quality hospice use, with the model in the earlier 
period explaining 8.7% of the quality hospice use difference between blacks and whites 
and 11.1% in the later period.  This means that the disparity in quality hospice use 
remains largely unexplained in both the earlier and later time period. 
 Repeating the PB analysis in a cohort that comes only from registries where black 
beneficiaries comprise greater than 5% of the study population yielded importantly 
similar results.  The disparity in hospice use and quality hospice use was similar to the 
whole population and did not change over time.  While the amount of the disparity in 
hospice use that is explained by the model did not decrease over time when limited to 
these registries (it instead varied between 57 and 76%), the model could not explain the 
majority of the disparity in any time period. 
Discussion 
Our analysis finds significant racial differences in hospice use prior to death for 
elderly cancer patients in the Medicare population, even after controlling for 
socioeconomic, demographic, and clinical differences between the groups.   Both hospice 
use and quality hospice stays increased for both races as the number of hospices and 
hospice users has grown over time.  The use by blacks is lower than for whites and is not 
explained by other racial changes such, income, and location.  The increase in use was 
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greater for quality hospice use for both races.  However, racial disparity in quality use 
was less than overall use in all time periods. 
Multivariate logistic regression models with race included as a covariate estimate 
the average effect of independent variables on the dependent variables regardless of race. 
We chose the PB method for this analysis because it allows us to estimate the proportion 
of the disparity in hospice use that is not due to the covariates in the model.  For example, 
in a regression model with race as an independent variable, the association between 
marital status and hospice use is a weighted average of the association among blacks and 
whites.  In contrast, the PB method estimates the association only for whites.  Applying 
this estimated coefficient to the black population then contributes the difference in use if 
a black patient retained all their demographic and clinical characteristics (including 
marital status) but was instead white.   
The PB method also does not assume that the effect of race is the same for all 
individuals.  Instead, the disparity remaining after adjustment is estimated for each 
individual. In this case, the intuition from the PB method did not differ from multivariate 
logistic regression; there was a significantly smaller odds of blacks using hospice 
compared to non-Hispanic whites (results available on request) in each time period. 
The findings from the PB method show that racial disparity in hospice use 
remains despite the increase in use by groups with characteristics that correlate with 
minority status (e.g., lower income, lower education, and non-married). 4,16  Changes in 
the availability of hospice and the hospice setting have not equalized the disparity.  
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Instead, although the hospice use of both groups has increased by approximately 50%, 
the magnitude of the disparity attributed to known factors remains unchanged. 
The disparity in hospice use between whites and blacks is not a new 
finding,31,36,58,81,82 but we show that it has not changed over time, and that it cannot be 
accounted for by differences in population demographic and clinical characteristics.  In 
our study population, the difference in quality hospice use among whites and blacks is 
smaller than the difference in overall hospice use, and only a very small portion of the 
difference in the earliest and late time periods can be explained by differences in other 
characteristics.   
Hospice utilization prior to death is neither possible nor appropriate for all people.   
We chose to study patients with cancer because they often experience a trajectory of 
dying with a predictable decline in the months prior to death that is compatible with 
earlier entry into hospice.10 The benefit of the SEER-Medicare database is that it provides 
information about disease characteristics so that our study population is limited to those 
who have few curative options making every person essentially eligible for hospice at 
diagnosis.  There is a growing disparity in hospice use between blacks and whites with 
noncancer diagnoses.84 
We do not have information regarding whether patients in our study were offered 
hospice care, despite being eligible. A recent study of patients with metastatic lung 
cancer found that only half of the patients had a discussion about hospice with a provider 
within 4 to 7 months of diagnoses, with blacks having lower rates of discussion than non-
Hispanic whites.85  Our data do not include information about whether hospice care was 
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available where the patient lived. Our measure of quality hospice care is based on length 
of stay only and does not measure other aspects of hospice quality that may be different 
over time and across racial groups. Patients can benefit from a short stay in hospice prior 
to death, but the time for patient and family to spend together after accepting death must 
be balanced with the stress of transferring care. 
Some studies have reported that blacks are more likely to prefer aggressive care 
and/or reject hospice care.36,86 Lack of communication about end of life care85 and lack of 
knowledge about the services provided by hospice may be more of a barrier for blacks.19  
There may be important confounding that exists due to lack of access to health care and 
revealed care preferences,87 and it is important to note the disparity between blacks and 
whites in cancer care received is not limited to use of hospice services—it begins at 
diagnosis.50,88  It is also possible that hospice is less likely to be available in places where 
high proportions or minorities reside,20 and that lower hospice use overall among health 
centers where blacks are more likely to receive care are is an important contributor.21  
These possibilities deserve further exploration. 
We found that while hospice use increased from 1992-2008 for non-Hispanic 
whites and blacks with cancer, the increase has not lessened disparities in use between 
these groups.  Different patterns were found for quality hospice use versus any hospice 
use.  The increase in quality hospice use for both groups from 1992-2008 is smaller, and 
the disparity in quality hospice use between blacks and non-Hispanic whites is smaller in 
all time periods.  This suggests that some of the overall increase in hospice use may in 
fact signal growing use of hospice as a place to die rather than a means of symptom 
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management and increasing social support prior to death.  Further research on how the 
black experience leads to lower hospice utilization is necessary for policy direction. 
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Figure 2a and b.  Percent of pancreatic, lung and gastric cancer decedents who used 
hospice (a) and who used “quality” hospice (b) among non-Hispanic whites, blacks, 
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Table 2.  Characteristics of lung, pancreatic and gastric cancer decedents from the 
SEER-Medicare data, 1992-2008, by race. 
    92-95   96-99   00-03   04-08   
    white black white black white black white black 
    overall overall  overall overall  overall overall  overall overall  







65-69 21.9% 26.1% 18.7% 23.1% 16.3% 22.8% 16.2% 21.1% 
70-74 27.7% 29.9% 26.9% 29.3% 25.4% 26.6% 23.3% 25.6% 
75-79 23.7% 22.6% 24.7% 22.1% 25.7% 24.6% 24.7% 23.5% 
80-84 15.8% 12.6% 17.7% 14.6% 18.9% 14.5% 20.3% 17.1% 
85+ 10.9% 8.9% 11.9% 10.9% 13.7% 11.5% 15.4% 12.7% 
Sex Male 56.0% 60.2% 53.0% 54.5% 52.0% 50.6% 50.5% 48.3% 
  Female 44.0% 39.8% 47.0% 45.5% 48.0% 49.4% 49.5% 51.7% 
Registry CT 17.5% 6.6% 18.4% 8.6% 17.2% 8.2% 17.5% 8.5% 
  Detroit 16.7% 43.3% 16.9% 45.7% 16.3% 39.6% 16.7% 38.3% 
  Seattle 15.8% 3.6% 17.1% 4.3% 17.2% 4.8% 17.6% 4.3% 
  
Atlanta/ 
Georgia 5.9% 18.1% 6.0% 17.9% 5.9% 20.6% 5.9% 21.4% 
  California 17.7% 25.1% 15.0% 20.3% 16.5% 23.4% 15.1% 23.9% 
  Other* 26.4% 3.3% 26.6% 3.2% 9.9% 3.4% 27.3% 3.6% 
Medicare FFS 88.6% 88.9% 81.6% 81.7% 79.2% 78.8% 81.9% 79.9% 






Single 5.8% 11.9% 6.3% 15.8% 6.5% 16.0% 6.5% 17.4% 
Married 53.8% 40.5% 53.0% 37.9% 51.4% 34.2% 50.8% 31.1% 
Previously 
Married 37.9% 44.6% 38.3% 42.2% 39.7% 45.8% 39.3% 47.9% 
Unknown 2.4% 3.0% 2.5% 4.1% 2.5% 4.0% 3.4% 3.6% 
Quartile Q1 21.4% 50.9% 21.0% 48.6% 20.0% 46.1% 19.3% 43.1% 
Education Q2 23.6% 25.3% 23.8% 25.3% 24.2% 27.2% 23.7% 28.0% 
  Q3 24.6% 15.0% 24.6% 17.0% 25.3% 17.2% 26.3% 19.2% 
  Q4 25.8% 5.4% 26.4% 5.4% 26.8% 6.2% 26.2% 5.8% 
  Unknown 4.5% 3.3% 4.2% 3.7% 3.8% 3.2% 4.6% 3.9% 
Quartile Q1 21.2% 71.7% 19.9% 67.6% 18.3% 63.8% 17.3% 60.8% 
Income Q2 25.2% 16.0% 24.0% 17.4% 24.4% 20.1% 23.2% 21.2% 
  Q3 25.0% 5.9% 25.9% 7.2% 26.2% 8.4% 26.6% 9.4% 
  Q4 24.0% 3.1% 26.1% 4.0% 27.3% 4.4% 28.3% 4.7% 
  Unknown 4.5% 3.3% 4.2% 3.7% 3.8% 3.2% 4.6% 3.9% 
Cancer Pancreatic 16.8% 19.4% 16.6% 18.4% 16.7% 17.4% 17.6% 20.2% 
  Lung 75.4% 69.3% 76.0% 70.7% 76.7% 72.4% 76.4% 71.3% 
  Gastric 7.8% 11.3% 7.4% 10.9% 6.6% 10.1% 6.1% 8.5% 
Stage Regional 23.6% 23.5% 26.8% 26.5% 28.1% 26.5% 26.3% 24.1% 
  Distant 60.7% 63.0% 58.8% 59.2% 61.8% 64.2% 65.7% 69.6% 
  Unknown 15.7% 13.4% 14.4% 14.2% 10.0% 9.3% 8.0% 6.3% 
*Other SEER registry=Utah, Iowa, New Mexico and Hawaii 
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Table 3. Peters Belson estimates of the disparity in hospice use between black and 
non-Hispanic white pancreatic, lung and gastric cancer decedents 
 
1992-1995 1996-1999 2000-2003 2004-2008 
Hospice Use     
Whites 36.1% 49.6% 58.2% 65.7% 
Blacks unadjusted 31.1% 42.6% 50.8% 57.0% 
Blacks predicted 30.8% 43.1% 52.4% 60.2% 
Unadjusted disparity 4.9% 7.0% 7.4% 8.7% 











 Quality Hospice Use     
Whites 24.7% 33.2% 37.2% 40.2% 
Blacks unadjusted 20.8% 28.4% 31.9% 35.5% 
Blacks predicted 24.4% 31.0% 35.2% 39.7% 
Unadjusted disparity 4.0% 4.8% 5.3% 4.8% 
Percent of disparity 
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Paper 2: Treatment intensity and use of hospice: Is hospice only for those who opt 
out of aggressive cancer treatment? 
 
Introduction 
Hospice is a team approach to pain and symptom management of a terminally ill 
patient that includes psychological, social and spiritual care of patients and their families. 
Since 1983, the Medicare program has covered hospice care with very specific conditions 
of participation—the patient must have a physician certify a prognosis of less than 6 
months to death, the patient must agree to accept that Medicare will not cover any 
curative treatment, and the care must be provided by Medicare certified hospices. The 
hospices are paid under a capitated payment system that emphasizes informal care of the 
patient in the home with hospice staff supplementing that care.18 
The Medicare Hospice Benefit (MHB) was explicitly offered as an alternative to 
curative care. Medicare will not pay for curative care after a patient is enrolled in the 
MHB unless the MHB is revoked by the patient. A patient entering hospice, therefore, 
must accept a terminal prognosis and not rely on treatments for life extension.89 Perhaps 
because of this, the conventional wisdom is that patients who choose hospice prefer less 
aggressive treatment, as evidenced by concerns about selection bias in studies of care at 
the end of life because hospice users would not have used aggressive care even in the 
absence of hospice care.90,91 However, a patient need not enter hospice immediately upon 
receiving a poor prognosis. A number of treatments may be tried prior to entering 
hospice; in fact, this may be necessary for the patient and provider to accept that death is 
inevitable. 
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Few studies have focused explicitly on the link between receipt of curative or life 
extending treatment given prior to hospice entry.  Most studies of hospice use have 
focused on describing whether hospice care was utilized prior to death and the length of 
stay in hospice.31,40,92 Results of such studies have revealed systematic variation in 
hospice use by age, race, marital status, geographic location, type of treating physician, 
and other non-medical factors. Paradoxically, many of the factors associated with a lower 
likelihood of using hospice are also associated with lower likelihood of receiving 
aggressive treatment (e.g., race and older age).48–50,93 Also, studies measuring medical 
costs prior to death have found that hospice users have higher medical costs than non-
hospice users. For example, Miller et al. studied nursing home residents and found that in 
the year prior to death (with a substantial amount of that time prior to hospice entry) 
mean expenditures were higher among the hospice users than the non-hospice users.64  
We hypothesize that patients receiving fewer aggressive and potentially curative 
treatments will use hospice less than patients who do not receive these potentially 
curative treatments. Lung cancer comprises an estimated quarter of all cancer deaths in 
2012.83 We focus on patients diagnosed with American Joint Committee on Cancer 
(AJCC) stage IIIa non-small cell lung cancer (NSCLC), and all stage IIIb NSCLC 
because these patients face poor prognoses (5 year relative survival:  24% for stage IIIA 
and <5% for stage IIIb) (internal SEER analysis) as well as plausible life extending 
treatment options. Our study provides an opportunity to examine hospice use among 
patients who have choices about whether to pursue life extending or palliative approaches 
to their cancer care. 
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Methods 
We received approval from the University of Minnesota Institutional Review 
Board (IRB) and SEER-Medicare program at the National Cancer Institute (NCI) to 
undertake this research project.  
We used the Surveillance, Epidemiology and End-Results (SEER)-Medicare 
linked database for this analysis.  The SEER data arise from a collection of population 
based tumor registries headed by the NCI. The SEER database contains uniformly 
collected data for analysis across registries. With the addition of four registries in 2000, 
there are a total of 16 SEER areas, representing 25% of the United States population with 
cancer. The SEER data contain date of diagnosis, stage and grade at diagnosis, histology 
of the tumor, initial surgical or radiation treatment recommended or provided, follow-up 
on vital statistics, cause of death, and patient demographic characteristics. Linkage with 
Medicare administrative data allows analysis of health care utilization before and after 
diagnosis and prior to death, with SEER data providing key information about the stage 
and grade of the cancer at diagnosis and treatment recommended at the time of 
diagnosis.74  
We limited our cohort to elderly patients residing in SEER areas who were 
diagnosed with stage III NSCLC between 2000 and 2006. We excluded those people who 
were unlikely to have complete claims (those ever enrolled in Medicare managed care or 
who were not enrolled in both Medicare Parts A and B) for the duration of the study. We 
followed people from 12 months prior to diagnosis (to understand underlying 
comorbidities) until death or the end of 2007. We did not include patients who were 
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diagnosed in Louisiana in 2005 due to the disruption to the SEER registry caused by 
Hurricane Katrina. We excluded patients who were diagnosed with any other cancer prior 
to or after their lung cancer diagnosis to ensure that: 1)  a uniform population was 
followed and 2)  cancer treatments were given for  lung cancer. (See appendix for 
complete cohort ascertainment). 
We used Medicare billing codes to document surgical treatment (resection), 
radiation therapy and chemotherapy received by the patient following diagnosis (see 
appendix for billing codes used). We followed the approach outlined by Davidoff et al. 
(2010) to determine whether patients likely received a single course of chemotherapy or 
multiple courses.94  Briefly, we defined a course as any agent initiated within 29 days of 
the start of a course of chemotherapy.  Initiation of a second agent after 29 days or after a 
45 day period without claims was considered a second chemotherapy treatment.  We 
summarized the treatments received as the count of treatments, and receiving two distinct 
courses of chemotherapy counted as two treatments.  For example, we considered a 
patient receiving radiotherapy and two courses of chemotherapy to have received three 
treatments (Table 1). 
We controlled for factors associated with the use of hospice other than treatment: 
sex (reported by Medicare), race and ethnicity (reported by SEER), stage at diagnosis 
(IIIa vs. IIIb), age at diagnosis, and registry.  We also measured comorbidities in the 12 
months prior to diagnosis using the Charlson score method described by Klabunde et al. 
(1999).95 
The primary outcomes of interest are use of hospice prior to death and length of 
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stay in hospice among hospice users. We defined use of hospice as one or more claims 
for hospice care after diagnosis and prior to death. We examined diagnosis codes for 
hospice and found that 92% had a diagnosis of lung cancer or other respiratory diagnosis 
on at least one hospice claim. We excluded patients (<1%) who appeared to have used 
hospice prior to the lung cancer diagnosis in the claims because they may have had 
another serious illness for which they received our treatments of interest.  We determined 
length of time in hospice using the time from the hospice start date to the Medicare date 
of death (obtained from social security records).  
We used the first date of cancer diagnosis in the Medicare claims as the diagnosis 
date.  This diagnosis date matched the SEER month of diagnosis in 80% of the cases, and 
was within one month for an additional 10% of cases.  Time from diagnosis to hospice 
use was determined by measuring the number of months from the diagnosis date to the 
start date on the first hospice claim.  
We also measured months of survival after diagnosis.  Overall survival was 
measured as death from any cause, and cancer-specific survival measured deaths 
attributed to cancer on the death certificate.  
Analysis 
We measured the bivariate association of treatment use with demographic and 
clinical characteristics using the chi-square test to detect statistically significant 
differences. 
We used Kaplan-Meier survival curves to describe the relationship of treatment 
use and survival (overall and cancer specific), time to initiation of hospice and, among 
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hospice users, time in hospice. For overall survival, we censored individuals at the end of 
the observation period. For cancer-specific survival, we censored individuals at non-
cancer death or alive at the end of the observation period. We censored individuals at date 
of death (for non-hospice users only) or the end of the observation period when 
measuring time to hospice use and time in hospice. 
We examined the association of aggressive treatment with hospice use after 
adjusting for known confounders (age, race, sex, registry, stage, and comorbidities) using 
multivariate logistic regression. This analysis included only patients who died during the 
observation period. 
We used multivariate Cox proportional hazards models to estimate the association 
of treatment with the hazard of dying and of using hospice after adjusting for known 
confounders. Among hospice users, a multivariate Cox proportional hazards model was 
used to estimate the association of treatment with the length of enrollment in hospice.   
We censored observations as described above. 
Sensitivity analysis 
As a sensitivity analysis, we excluded patients from the analysis of ‘time in 
hospice’ if their date of discharge did not match the date of death (2.4% of cases). We 
also determined if results would change if the SEER diagnosis month and year were used 
(with the 15th of the month as the proxy day).  Our findings did not change in either case.   
Results 
We identified 9,400 patients older than 66 who were diagnosed with stage IIIA or 
IIIB NSCLC in SEER between 2000 and 2006 (excluding pleural effusion). Three 
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quarters (n=7,154) died before the end of 2007. Median cancer-specific survival was 12 
months among patients with stage IIIA disease and 9 months among patients with stage 
IIIB disease.  Patients were evenly distributed among the treatment groups: 25% received 
no treatment, 25% received one treatment, 22.5% received 2 treatments, and 27.2% 
received 3 treatments.  Radiation was the most common single treatment received at 
16.8%, a combination of radiation and chemotherapy was the most common in the two 
treatment group at 16.0% and the most common three treatment combination was 
radiotherapy and two rounds of chemotherapy (18.6%).  The amount of treatment 
received varied by age, race, stage, registry, comorbidity score and year of diagnosis (all 
p<0.05, Table 2). Hospice use did not vary significantly by treatment level (p=0.11). 
Cancer-specific survival 
Analyses with either unadjusted Kaplan-Meier and multivariate cox models 
indicated that patients who used more treatments survived longer (Figure 1). The median 
cancer-specific survival among patients varied by amount of treatment for patients with: 
no treatment, 4 months; one treatment, 8 months; two treatments, 11 months; and three 
treatments, 21 months (log rank p-value: <0.0001). The multivariate Cox proportional 
hazards model found that patients who received no treatments had an increased hazard 
ratio of mortality of 3.4 (chi-square p-value <0.0001) compared with patients receiving 
three treatments (Table 2). Increasing age and comorbidity score and diagnosis in earlier 
years were also associated with significantly shorter time to death, while Hispanic white 
and Asian/Pacific Islander had significantly longer time to death compared to non-
Hispanic whites (Table 2). 
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Hospice use 
Among patients who died of cancer prior to 2008, receiving fewer treatments was 
not associated with a significant difference in the propensity to use hospice with the 
exception of patients using two treatments who were significantly less likely to use 
hospice than patients receiving three treatments (OR: 0.835, p=0.012; Table 4). Factors 
associated with propensity to use hospice were age over 75 years (vs. <70), female sex, 
and diagnosis in later years (Table 4). 
While the number of treatment types did not predict hospice use, the number of 
treatment types was significantly related to time to enter hospice. Predicting time to 
hospice found that patients receiving fewer treatment types had a much shorter time from 
diagnosis to hospice compared to patients receiving three or more treatments (HR: 3.85, 
p-value <0.0001; Table 3). 
Among hospice users, the amount of time spent in hospice varied with the amount 
of treatment received prior to hospice entry (log rank p=<0.0001, Figure 2). Patients who 
had no treatment had the longest median time in hospice (28 days), while patients who 
had 3 or more treatment had the shortest median time in hospice (16 days). Patients who 
used 0, 1, and 2 treatments experienced a longer stay in hospice compared to patients 
with three or more treatments (HR: 0.759, p<0.0001, HR: 0.874, p=0.003, and HR: 0.886, 
p=0.01, respectively, Table 5). While very short stays (less than three days) were 
common, patients with 3 or more treatments were most likely to experience a stay of less 
than three days (3 treatments, 31.1%; two treatments, 19.3%; one treatment, 24.3%; and 
no treatments: 25.3%; chi-square p-value <0.0001, data not shown in table).  
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Discussion 
In our analysis, we found that patients who received more treatment were as likely 
to use hospice as patients receiving less or no treatment; however, patients with more 
treatment did experience significantly shorter stays in hospice and had a longer time to 
hospice enrollment after diagnosis. Our population based findings mirror a recent single 
institution study examining resource use at the end of life among patients with advanced 
lung cancer which found that while 65% of patients used hospice prior to death, length of 
stay in hospice was short and many patients (40%) were receiving anticancer therapy 
within 30 days of death.96   
One of the purposes of the MHB when enacted was to reduce costs associated 
with end of life care by substituting palliative care in the home for intensive treatment 
and crisis symptom relief.  In our analysis, 46% of hospice patients who used hospice 
also received more than two anti-cancer treatments prior to hospice entry. In these cases, 
hospice use complements anticancer therapy rather than providing a substitute.  While we 
have not included costs in this analysis, intensive use of treatment prior to hospice has 
cost implications. Studies of cost savings from hospice have been inconclusive;62,64,90,91 
this may be attributed, in part, to the time window chosen—if patients who use hospice 
also use expensive treatments prior to hospice entry, any window including this time 
period may find that hospice patients are more expensive due to use of both life 
extending therapy and palliative care.62   
Due to the benefits of hospice,2 concerns have arisen about patients who do not 
access the benefit because they want to purse life extending treatment.36  Some have 
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advocated for reform of end of life care that embraces the combination of anti-cancer 
therapy and palliative care. Open access hospice or initiating palliative medicine 
consultation beginning at diagnosis are two common suggestions.97 In the open access 
hospice model, curative treatment need not be abandoned before enrolling in hospice 
care. Consultation with a palliative medicine specialist provides the patient with an expert 
to evaluate pain and symptom management as well as psychosocial needs while curative 
treatment is received.  A recent small study found that when enrolled in early palliative 
care, patients experienced longer length of stay in hospice and were less likely to have 
received chemotherapy within 60 days of death but were not less likely to receive 
anticancer treatments overall.98  
It seems possible that some patients in our analysis who chose life-extending 
treatments did not have the chance to benefit from hospice because they died while 
receiving treatment. Reforms would allow these patients to benefit from palliative 
services. The open access hospice model or early initiation of palliative care may not 
save money by avoiding intensive treatment; however, both models may prevent 
expensive hospitalizations for managing symptoms associated with the dying process as 
well as providing psychosocial support to the patient and family. 
Whether or not the hospice program is changed to allow for the receipt of curative 
treatment, seriously ill patients should receive information about hospice, regardless of 
their current treatment choices as we have shown that patients receiving life-extending 
treatment need not be opposed to hospice use.  Providing information about hospice 
early, with the understanding that patients are not ready for the benefit but may become 
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so in the future may help to increase the length of stay in hospice since patients with short 
stays are unlikely to experience the full benefit of hospice.99 
  The strengths of this analysis lie in the prospective design, the selection of a 
population for whom therapy may provide some survival benefit but declining treatment 
is equally rational, and use of the population-based data. However, this is an analysis of 
administrative data, and only information collected for the purposes of Medicare billing 
and cancer registration are available to our analysis. There is no information about the 
treatment options offered to patients, particularly when or if patients are offered hospice.  
In addition, it is impossible to know whether patients who received more treatment 
survived longer because of their treatments or used more treatment because they survived 
longer.  Thus, this work should not be seen as evidence that aggressive treatment for 
patients with stages IIIa and IIIb NSCLC improves survival. 
Our analysis finds that patients who opt to receive rigorous life-extending 
treatments are as likely to use hospice as those who choose no treatment.  It may be time 
to change the view of hospice as a substitute for curative or life-extending treatment to 
that of hospice as a complement to life-extending treatment.  Changing our approach may 
lend more coherence to payment policy reform and allow for a focus on the goals of care 
rather than the care itself.   
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Table 4. Treatments used in each treatment category 
 
  N % 
No treatment  2372 25.2 












2 Treatment  
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Table 5. Population characteristics by treatment type, including hospice use 
Number of Treatments 0 1 2 3 p-value 









% who died before 2008 82.5% 78.4% 76.4% 67.8%  
Hospice use among decedents 56.8% 57.7% 54.1% 57.8% 0.1057  
Age (years) 66-69 15.5% 13.5% 23.7% 30.0% <0.0001 
  70-74 23.1% 24.1% 32.6% 36.2%   
  75-80 26.1% 29.6% 27.3% 22.9%   
  80+ 35.3% 32.8% 16.5% 11.0%   
Race Non-Hispanic white 80.6% 82.4% 85.2% 85.6% <0.0001 
  Black 11.1% 9.6% 7.1% 6.8%   
  Hispanic  4.6% 4.0% 3.4% 3.5%   
  Asian/Pacific Islander 3.3% 3.8% 3.7% 3.9%   
Sex Male 57.6% 52.8% 55.8% 55.7% 0.011 
  Female 42.4% 47.2% 44.2% 44.3%   
Stage Stage IIIa 54.1% 56.3% 53.6% 59.6% <0.0001 
  Stage IIIB 45.9% 43.7% 46.4% 40.4%   
Charlson score 0 40.5% 38.2% 44.9% 49.4% <0.0001 
  1 27.7% 31.3% 33.5% 32.4%   
  2+ 31.8% 30.5% 21.6% 18.1%   
Registry San Francisco 4.0% 3.1% 2.2% 2.8% <0.0001 
  Connecticut 5.8% 8.0% 7.0% 8.6%   
  Detroit 8.1% 7.6% 8.7% 9.2%   
  Hawaii 1.6% 1.6% 1.6% 1.8%   
  Iowa 5.0% 6.7% 7.1% 7.3%   
  New Mexico 2.1% 1.7% 1.9% 1.3%   
  Seattle 7.1% 4.8% 6.1% 5.5%   
  Utah 1.4% 1.0% 1.5% 0.9%   
  Atlanta 3.4% 2.5% 3.2% 3.0%   
  San Jose 1.1% 2.0% 2.1% 2.2%   
  Los Angeles 4.8% 4.7% 5.5% 5.2%   
  Greater California 19.7% 16.0% 15.4% 18.3%   
  Kentucky 13.7% 12.5% 12.6% 11.7%   
  Louisiana 8.5% 11.3% 8.8% 7.3%   
  New Jersey 13.1% 16.1% 15.8% 14.5%   
 Year of death 2000 11.8% 15.0% 13.7% 11.9% <0.0001 
  2001 14.5% 15.7% 14.0% 12.1%   
  2002 14.9% 14.8% 15.6% 12.0%   
  2003 16.1% 15.5% 15.4% 15.5%   
  2004 14.7% 14.4% 14.3% 17.2%   
  
  
2005 14.8% 12.7% 14.1% 14.9%   
2006 13.2% 11.9% 12.8% 16.5%   




Never Married 8.5% 7.2% 6.0% 5.6% <0.0001 
Married 41.8% 44.6% 54.6% 59.8%   
Previously Married 44.9% 43.7% 35.5% 31.3%   
Unknown 4.6% 4.5% 3.9% 3.4%   
 Zip code median 
income 
   
  
Q1 27.5% 24.3% 23.0% 20.9% <0.0001  
Q2 24.7% 24.3% 23.1% 23.5%   
Q3 22.9% 23.4% 25.6% 24.6%   
  Q4 20.5% 24.0% 23.9% 26.5% 
Unknown 14.5% 15.7% 14.0% 12.1% 
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Table 6.  Multivariate cox proportional hazards models* predicting cancer specific 
mortality and time to hospice use 
  Cancer specific mortality  Time to hospice 












Treatments 0 3.363 3.139 3.603 <.0001 3.822 3.501 4.173 <.0001 
  1 1.919 1.792 2.056 <.0001 1.855 1.698 2.025 <.0001 
  2 1.537 1.435 1.646 <.0001 1.464 1.34 1.6 <.0001 
  3 1.0 
  
 1.0     
Age 66-69 1.0  
  
 1.0     
  70-74 1.106 1.032 1.184 0.0041 1.1 1.004 1.205 0.0413 
  75-80 1.249 1.164 1.341 <.0001 1.406 1.282 1.542 <.0001 
  80+ 1.328 1.234 1.43 <.0001 1.681 1.53 1.848 <.0001 
Race Non-Hispanic 
white 1.0  
  
 1.0     
  Black 0.989 0.905 1.079 0.7975 0.981 0.875 1.1 0.7451 
  Hispanic 0.862 0.761 0.977 0.0199 0.909 0.773 1.068 0.2446 
  Asian/Pacific 
Islander 0.781 0.671 0.909 0.0014 0.644 0.518 0.801 <.0001 
Sex Male 1.0  
  
     
  Female 0.853 0.81 0.897 <.0001 1.003 0.94 1.07 0.9277 
Stage Stage IIIa 0.721 0.688 0.756 <.0001 0.727 0.684 0.772 <.0001 
  Stage IIIB 1.0     1.0     
Charlson 0 1.0  
  
 1.0     
  1 1.132 1.072 1.196 <.0001 1.159 1.081 1.244 <.0001 






Never Married 1.0     1.0     
Married 1.05 0.953 1.157 0.3224 0.909 0.793 1.042 0.909 
Previously 
Married 1.046 0.991 1.104 0.0995 1.127 1.053 1.207 1.127 
Unknown 0.974 0.86 1.102 0.6732 0.973 0.827 1.144 0.973 





Q1 1.0    1.0    
Q2 0.979 0.915 1.048 0.5427 0.922 1.103 0.8566 0.922 
Q3 0.937 0.875 1.004 0.0636 0.964 1.151 0.2526 0.964 
Q4 0.902 0.842 0.967 0.0038 0.953 1.139 0.3665 0.953 
Unknown 0.905 0.797 1.027 0.1207 0.892 1.227 0.5808 0.892 
*Models included SEER registry and diagnosis year; observations are censored at non-cancer death and 
end of the observation period. 
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Table 7.  Logistic regression predicting hospice use among lung cancer decedents 





Treatments 0 0.892 0.775 1.026 0.0992 
  1 0.915 0.794 1.053  
  2 0.838 0.728 0.965  
  3 1.0  
  
 
Age 66-69 1.0  
  
<0.0001 
  70-74 0.933 0.811 1.073  
  75-80 1.169 1.012 1.35  
  80+ 1.433 1.231 1.667  
Race Non-Hispanic white 1.0  
  
0.0610 
  Black 1.067 0.891 1.277  
  Hispanic White 1.051 0.814 1.357  
  Asian/Pacific 
Islander 0.671 0.492 0.913 
 
Sex Male 1.0  
  
<0.0001 
  Female 0.714 0.644 0.793  
Stage Stage IIIa 1.075 0.976 1.184 0.1447 
  Stage IIIB 1.0     
Charlson 
Score 
0 1.0  
  
0.7054 
1 0.98 0.875 1.097  
  2+ 0.949 0.84 1.073  
Diagnosis 
year 
2000 1.0  
  
0.0034 
2001 1.053 0.883 1.257  
  2002 1.273 1.064 1.522  
  2003 1.059 0.889 1.262  
  2004 1.284 1.072 1.537  
  2005 1.334 1.107 1.606  




   
Never Married 1.0  
  
<0.0001 
Married 0.683 0.56 0.834  
Previously Married 1.146 1.025 1.281  
Unknown 0.932 0.724 1.2  




Q1 1.0  
 
1.0  0.0003 
Q2 1.064 0.926 1.222  
Q3 1.222 1.062 1.407  
Q4 1.357 1.176 1.566  
  Unknown 1.126 0.869 1.458  
*Model included SEER registry. 
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Table 8. Mutivariate Cox proportional hazards model predicting mortality after 
hospice entry 





Treatments 0 0.775 0.708 0.849 <.0001 
  1 0.888 0.812 0.972  
  2 0.891 0.812 0.977  
  3 1.0  
  
 
Age 66-69 1.0  
  
0.2639 
  70-74 0.924 0.84 1.016  
  75-80 0.952 0.866 1.047  
  80+ 0.914 0.83 1.007  
Race Non-Hispanic white 1.0  
  
0.1575 
  Black 1.033 0.915 1.166  
  Hispanic White 0.848 0.714 1.006  
  Asian/Pacific Islander 0.871 0.695 1.092  
Sex Male 1.0  
  
0.0002 
  Female 0.88 0.822 0.942  
Stage Stage IIIa 0.979 0.92 1.043 0.5134 
  Stage IIIB 1.0     
Charlson 0 1.0  
  
0.6706 
  1 1.013 0.942 1.09  
  2+ 1.037 0.957 1.124  
 Marital 
Status 
    
Never Married 1.0    0.0421 
Married 0.912 0.789 1.053  
Previously Married 0.922 0.858 0.99  
Unknown 0.837 0.707 0.991  




   
Q1 1.0 (ref)   0.2224 
Q2 1.011 0.92 1.11  
Q3 1.033 0.942 1.133  
Q4 1.047 0.953 1.149  
Unknown 0.858 0.722 1.019  
*Models included SEER registry and diagnosis year; observations are censored at non-
cancer death and end of the observation period; this model only includes hospice users. 
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Figure 3.  Kaplan-Meier curves depicting time from diagnosis to death from cancer 
(a) and time from diagnosis to hospice entry (b) among all Medicare beneficiaries 
with stage III lung cancer, by number of treatments 
(a) Unadjusted time to death from cancer 
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Figure 4.  Kaplan-Meier curves depicting time from hospice entry to death among 
Medicare hospice users with stage III lung cancer, by number of treatments. 
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Paper 3: Place of death in terminal cancer: does hospice mean death at home?   
 
Introduction 
Hospice was introduced to the United States in the 1970’s as an alternative way of 
caring for dying patients, particularly as an alternative to institutionalized death.  
Improvements in medical technology enabled doctors to prolong life for patients, which 
often meant that death occurred within the walls of a hospital while under the care of a 
physician. The first hospices provided care in small home-like hospice buildings separate 
from hospitals or in patient’s homes and focused on both physical and psychosocial care 
giving for the patient and family.  While life-prolonging care in an institution was costly 
physically, emotionally, and financially, the focus of hospice was quality of life in the face 
of impending death.11,89,100 Hospices were originally developed with diagnoses like cancer 
in mind, whereby a patient experienced a relatively predictable decline towards death.10  
When the Medicare Hospice Benefit (MHB) was first introduced in the Tax 
Equity, Fairness and Responsibility Act of 1982 (TEFRA), it proposed dual purposes of 
cost containment and improving the quality of life for Medicare beneficiaries who were 
dying.  Central to both of these purposes was the idea that hospice services would 
primarily be delivered in patients’ homes, where the patient would be surrounded by a 
familiar environment and family members. The MHB’s payment design favors home care 
and TEFRA included a limitation of a hospice provider’s total inpatient care days to 20 
percent of all care days provided by the hospice during the year.17  
Given this history, it is not surprising that to hear the word “hospice” is to think of 
a patient dying at home.  However, use of hospice has changed a great deal since the MHB 
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was enacted in 1983; the number and type of hospices as well as the way they provide care 
has grown in tandem with large increases in the number of Medicare beneficiaries electing 
hospice.   
The purpose of our analysis is to answer the question, “Is the MHB a home-based 
benefit?”   Previous analyses that have addressed the question of location of death among 
patients enrolled in hospice have done so within the context of a single hospice provider or 
small number of hospices.99,101,102 In 2007, Medicare began collecting information on the 
location of service (LOS)103 to better understand trends in utilization of the MHB, 
allowing us to answer the question on a much larger scale.  We use this information to 
study some of the prototypical home hospice users—cancer patients--to understand which 




Our analysis was approved by the University of Minnesota Institutional Review 
Board. 
The SEER-Medicare linked data combines information collected from the 
population-based Surveillance, Epidemiology and End Results (SEER) cancer registries 
with Medicare claims data.  The linked database covers approximately 25% of the elderly 
cancer patients living in the United States.  The benefit to using linked SEER-Medicare 
for this analysis is the ability to limit the population to those who died of their cancer and 
to include additional information about the cancer diagnosis not found on claims. 
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We chose to study patients with breast, lung, colorectal, prostate and pancreatic 
cancer because these make up the largest proportion of deaths from cancer.83  We 
identified men and women who were diagnosed with these cancers while residing in 
SEER areas and who subsequently died from their cancer (as reported by the SEER 
program based on death certificate information) in 2007 or 2008.   Patients whose 
discharge status on the last claim indicated that the patient was still alive and whose 
Medicare date of death was later than the end date of the last hospice claim, indicating a 
possible live discharge104 were excluded from this analysis. Second, patients with 
unknown race or race other than white, black, Hispanic or Asian were excluded due to 
small numbers (n=30).  The full cohort definition can be found in the appendix. 
We first examined the association between location of care and the level of care 
(LOC) to evaluate the new field on Medicare Hospice claims.  The location of care was 
determined by the healthcare common procedure coding system (HCPCS) code on the 
hospice claim.  LOC describes the intensity of care (routine home care, continuous home 
care, respite inpatient care to provide relief for caregivers, and respite inpatient care for 
intensive pain and symptom management) and is found in the revenue center field.  For 
our purposes, HCPCS codes were grouped into home (home or assisted living facility), 
nursing home (unskilled and skilled nursing facility), hospital (inpatient hospital), hospice 
(inpatient hospice facility) and other (long-term care hospital, inpatient psychiatric facility 
and ‘not otherwise specified’) (Table 1). 
The location of death (LOD) is the location of care on the final hospice claim. We 
used the chi-square test to find meaningful differences in hospice use and LOD by age, 
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sex, race, urban/rural location, registry, health maintenance organization (HMO) 
enrollment and type of cancer as well as differences in length of stay by location of death. 
Length of stay was measured as total time enrolled in hospice, using claim dates.  
Approximately 10% of hospice enrollees experienced a break in use (defined as more than 
one day between the end of one claim and the beginning of the next); days during these 
breaks are not included in the total length of stay. HMO enrollment was measured during 
the month of hospice entry because we were interested in the effect of HMO enrollment 
on hospice entry and found that most participants remained enrolled from hospice entry to 
death; less than 1% of hospice users in our study population were enrolled in an HMO at 
hospice entry switched to fee-for-service (FFS) prior to death. 
We used multivariate logistic regression analyses to find the association of age, 
sex, race, registry, urban/rural status, HMO enrollment, cancer type, and quartile of 
median income in the zip code of residence with each dependent variable—hospice use 
and death at home.  An additional logistic regression analysis was performed to examine 
the association of location of death on the dependent variable optimal length of stay 
(greater than 7 days and less than 180 days) while controlling for the presence of age, sex, 
race, registry, urban/rural status, HMO enrollment, cancer type, and quartile of median 
income in the zip code of residence.  
Results 
 We identified 46,044 patients who died of cancer from 2007 to 2008, and 30,534 
(66.3%) of these patients used hospice prior to death. Upon examining all hospice claims 
(i.e., not simply final claims) for this population, we found that the location of care cannot 
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be inferred from the level of care code alone.  Table 2 describes the association of the 
LOC and LOD codes among all hospice claims filed for our study population from 2007-
2009.  The majority (86.2%) of claims that were billed for routine home care (RHC) and 
90% of these indicated a home setting as LOC, with 11.7% and 8.2% provided in a 
nursing home setting.  Over 800 claims for RHC indicated an inpatient hospital as the 
LOC, and over 400 claims for general inpatient care (GIP) indicated a home setting as the 
LOC. 
Among hospice users, location of death varied significantly by the age of the 
hospice enrollee at death (p<0.0001).  The proportion dying at home decreased as patient 
age increased from 73.2% of enrollees aged 65-69 to 66.9% of enrollees over 85.  Older 
hospice enrollees were much more likely to die in a nursing home (19.6% of over 85 year 
olds vs. 8.1% of enrollees aged 65-69). Sex was also significantly associated with location 
of death, although the differences were small; men were slightly more likely to die at 
home and women to die in a nursing home. Hispanic enrollees were much more likely to 
die at home (76.4%) and blacks the least likely (62.9%) compared to other racial and 
ethnic groups.  Blacks were most likely to die in nursing home, hospice, and inpatient 
hospice (Table 3).  
Hospice enrollees who were enrolled in a Medicare FFS were less likely to die at 
home than patients enrolled in Medicare HMO (67.3% vs. 76.4%) and more likely to die 
in a hospital (7.6% vs 3.8%). Hospice enrollees dying of breast and prostate cancer were 
the least likely to die at home (65.9% and 67.9%, respectively), and those dying of 
pancreatic cancer were the most likely to die at home (73.6%) (Table 3). 
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Younger patients, men, blacks and Asians (vs. whites and Hispanics), FFS users, 
unmarried people, and patients from areas with lower income were less likely to use 
hospice when controlling for all factors (Table 4).  There is significant variation by SEER 
registry, e.g. for the registry with the most hospice users (Iowa) and the registry with the 
least (Los Angeles), the odds ratio was 0.31 (95% CI: 0.27-0.35). 
In regression analysis predicting death at home (Table 4), geography remained the 
most important predictor among hospice users with an odds ratio of 10.96 between the 
registry with the most home deaths (San Francisco) and the registry with least (Iowa).  
Older patients, patients in urban areas (vs. rural areas (OR: 0.61, 95% CI: 0.48, 0.77)), 
patients enrolled in FFS Medicare (vs. Medicare HMO (OR: 0.85,95% CI:  0.80, 0.91)), 
and those who were never married (vs. those who were married (OR: 0.52, 95% CI: 0.47-
0.57) were less likely to die at home. 
Hospice patients who died in the hospital were more likely than patients who died 
at home to have a length of stay of less than 7 days (66.9% vs 33.3%, respectively, Figure 
1). Location of death was a significant predictor in a multivariate logistic regression model 
predicting inappropriate length of stay (Table 5).  Patients dying in hospitals (OR 4.307, 
95% CI: 3.884-4.775), inpatient hospice (OR: 1.56, 95% CI: 1.434-1.698), and nursing 
homes (95% CI: 1.137, 95% CI: 1.056-1.224) have a higher propensity toward short stay 
(≤7 days) than patients dying at home after controlling for all other measured factors, 
while patients dying in nursing homes have a greater odds of long lengths of stay (>180 
days)  (OR: 1.506, 95% CI: 1.301-1.743).   
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Discussion 
Almost one-third of patients using the MHB died in institutions.   Dying at home 
was more common among groups most likely to use hospice in previous studies:  younger 
patients, Hispanic and Asian patients, patients with pancreatic cancer, and patients 
enrolled in a Medicare HMO. 
Our findings may suggest that hospices have been successful in reaching out to 
groups for whom death at home was a barrier by providing hospice services in settings 
other than home.  For example, we find that among patients who use hospice, blacks are 
least likely to die at home.  Investigations into this phenomenon have found that black 
patients often wish not to burden their family caregivers at the end of life or have no 
access to an informal caregiver35,105 and therefore could not benefit from hospice provided 
only in the home.  Indeed, we, along with many others,30,36,58,78,87 find that blacks are the 
racial group least likely to use hospice. Similarly, patients who were never married or 
those with limited resources may not have access to family caregivers,76 and we find that 
they are least likely to use hospice and least likely to die in the home when hospice is 
accessed. 
We find that patients enrolled in an HMO are also more likely to die at home.  This 
is an interesting finding in that deserves further attention—the MHB is a carve-out, and 
one would expect that HMO and FFS patients would receive the same care once enrolled 
in the MHB. Patients enrolled in FFS Medicare have been found previously to enroll in 
hospice at higher rates than those enrolled in Medicare managed care organizations and 
have longer lengths of stay, a finding that is replicated here.  We also find an association 
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between LOD and length of stay; perhaps the association between HMO enrollment and 
longer hospice length of stay earlier may help to explain this finding. 
 We find that almost a quarter (23.5%) of hospice users were enrolled for less than 
3 days.   For years, hospice advocates have been hailing the growth in hospice use but 
have responded with trepidation to the increase in very short stays. The benefits of 
hospice—the opportunity for patient and family to come to terms with the impending 
death and access resources to help them emotionally, financially and physically—are 
diminished with very short stays.9  Transitioning from one provider to another can create 
significant organizational, financial, physical and emotional consequences for patients 
and caregivers.9,106   
Hospice patients dying in institutional settings have been shown to be more likely 
to have shorter stays.99,107 We find that  66.9% of patients who die in the hospital enrolled 
in hospice less than seven days prior to death, and 50.5% die within three days of 
enrolling in hospice.  These late enrollments probably signal the recognition of imminent 
death rather than a desire to transition goals of care.  It may be prudent to investigate the 
financial incentives leading to an increase in hospitals electing to discharge a patient to a 
hospice bed within the same institution.  Unlike discharges to other institutions, such as a 
skilled nursing facility, hospice discharges that result in a shorter than average hospital 
stay do not result in a reduction in reimbursement for the stay.  A hospital collects the full 
DRG payment (based on the average length of stay) and also collects the general inpatient 
payment per diem hospice rate.108 
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While we focus on predictors of hospice use, particularly in a home-based setting, 
we must note that death in the hospital may not be an adverse event.  For some, it may 
provide the welcome opportunity for patients and family members to remain under the 
care of the hospital staff who have become familiar to them during treatment or at least to 
have the comfort of professional caregivers.23  For others, however, it may be a protocol 
triggered by the recognition of imminent death, leaving patient and family members 
disoriented by the quick transition.  The fact that almost one-half of hospital deaths in 
hospice occurred in patients enrolled in hospice for less than three days may suggest the 
latter situation.   
 On the other hand, nursing home patients are more likely to have very long (>180 
days) stays in hospice.  Nursing homes are an institutional setting, but they are often 
where the patient resides. The Medicare benefit has allowed hospice care in nursing 
homes to be reimbursed as care at home (most often routine home care) since 1986. 
Nursing homes and hospice both have incentives to enroll residents in hospice care 
because of overlap of some services provided.  Dying nursing home residents may access 
hospice services in addition to their usual care routines (with the exception of patients 
using a Medicare reimbursed post-acute care skilled nursing facility visit—hospice is not 
reimbursed at this time).109 Nursing homes benefit by the fact that increased clinical 
personnel are available to the resident in their facility, and hospices benefit by serving 
multiple patients in one location.110 
These mutually beneficial arrangements may explain the widespread use of 
hospice in nursing homes, and this may explain some of our findings concerning the eldest 
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patients in our study population.111  We found that among elderly cancer patients, the 
oldest age group was most likely to use hospice, a finding that contrasts with previous 
findings.31,34 We also found that the oldest patients were least likely to have a home death. 
Concern about use of hospice in nursing homes has increased in the last decade as nursing 
hospice users within the nursing home population have substantially longer stays than 
others.111  It has been proposed that this is a result of inappropriate recruitment practices 
among hospices, especially by targeting patients with non-cancer diagnoses for whom the 
terminal decline is unpredictable and may be longer.  We find that even among patients 
admitted to hospice after diagnosis of cancer, the group most likely to have a stay of 
greater than 180 days is those who die in a nursing home. 
The benefits of hospice care extend to any patient who is terminally ill; however, 
patients with terminal cancer generally experience a dying trajectory most compatible with 
hospice—a relatively predictable decline.10   Our analysis provides current information in 
a representative population of Medicare beneficiaries with cancer.  While our study 
population does not include non-cancer hospice users, the fact that these patterns of use 
occur even among the prototypical hospice patients suggests that they will be present to an 
even larger degree among non-cancer hospice users.  The large extent of geographic 
variation even among the SEER registries suggests a need for further evaluation across the 
rest of the United States.  While our analysis focuses on the elderly population, our 
findings mimic other single and multiple hospice studies with no age restriction.99,101,107 
Patient factors such as lower functional or performance status, lack of caregiver (outside 
of what can be inferred by marital status) and other factors about the patient’s home which 
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may make it an unsuitable location to die may be important and are unmeasured here; 
however, this study is a large scale and finds general population trends. 
The MHB was designed based on the ideal of hospice as a non-institutional 
setting.  We found that almost a third of patients are not receiving home-based care at the 
time of death.  The decision must be made whether this signifies a need to revisit a) the 
benefit’s design to better match the original goals, b) the goals themselves, or c) the 
implementation of the benefit.  For each site of death, aligning payment incentives with 
goals of quality care at the end of life will aid in promoting better outcomes. Hospice 
provided within traditional institutions is necessarily different than hospice provided in 
the home, yet the payment level does not change whether RHC is provided in a nursing 
home versus home or GIC is provided in a hospital or a hospice.  The addition of HCPCS 
POS codes to administrative data collection in hospices is a step in the right direction.  
Using these codes will aid in developing optimal payment policy given how the hospice 
benefit is used at each site. These codes provide insight into the care that is received and 
illuminate the fact that “hospice” often does not equal “home.” 
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Table 9. Description of codes used to describe services provided (Revenue Center 
Codes) and location of services (CPT codes) on Medicare Hospice claims since 2007. 
Revenue Center Codes  
0651  Routine Home Care  
0652 Continuous Home Care  
0655 Respite care  
0656 General Inpatient Care  
  
 
CPT codes (HCPCS) Category 
Q5001 Home Home 
Q5002 Assisted Living Facility 
Q5003 Non-skilled Nursing Home Nursing Home 
Q5004 Skilled Nursing Facility 
Q5005 Inpatient Hospital Inpatient Hospital 
Q5006 Inpatient  Hospice facility Inpatient Hospice 




Q5009 Not Otherwise Specified 
Q5010 Hospice Facility* N/A 
 
*Code introduced in 2010 (after our period of study) to denote patients receiving care in 
a hospice residential facility (e.g., receiving routine home care while residing in a 
hospice facility). 
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Table 10.  Location of services by level of service type for any hospice claim filed for 
those in the study population, 2007-2008. 
 
 Home Nursing 
Home 
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Table 11. Characteristics of Medicare lung, breast, colorectal and pancreatic cancer 
decedents and location of death among hospice users, 2007-2008 
 
    Total    
Hospice 
users 
Location of death 
Home Nursing Home Hospital Hospice Other 
  Total 46044 30,534 21,412 4,049 1,960 2,830 283 





65-69 4385 58.80 73.20 8.10 7.90 10.10 0.60 
70-74 9246 63.40 71.90 9.40 6.80 10.80 1.10 
75-79 11100 65.90 71.20 11.00 7.00 9.80 1.00 
  80-84 10473 68.30 69.80 13.80 6.50 9.00 0.90 
  85+ 10840 70.30 66.90 19.60 5.00 7.60 0.90 
Sex* Female 23437 69.40 69.40 14.30 6.10 9.30 1.00 
  Male 22607 63.10 71.00 12.10 6.80 9.30 0.80 
Race* NH-White 37099 67.80 69.80 13.30 6.50 9.50 0.90 
  Black 3978 58.40 62.90 16.70 9.40 10.20 0.70 
  Hispanic 2827 66.70 79.10 10.10 3.20 6.40 1.20 





Big Metro 27594 66.50 70.50 13.00 7.20 8.50 0.90 
Metro 12180 68.70 70.20 12.60 3.90 12.20 1.10 
Urban 2405 61.10 73.00 13.90 6.80 ǂ ǂ 
  Less Urban 3181 60.40 66.30 17.10 8.80 7.00 0.80 




San Francisco 2372 62.90 83.70 9.50 1.30 3.00 2.50 
Connecticut 2570 63.00 51.60 20.00 14.50 13.20 0.70 
Detroit 2946 71.10 56.30 13.20 25.00 ǂ ǂ 
  Hawaii 751 56.70 68.10 4.20 6.80 17.40 3.50 
  Iowa 2543 78.30 42.20 26.30 10.10 20.60 0.90 
  New Mexico 1038 70.50 72.80 8.90 2.20 14.10 2.00 
  Seattle 2642 65.40 72.50 13.00 4.10 9.10 1.30 
  Utah 788 79.80 81.10 10.30 3.20 4.90 ǂ 
  Atlanta 1190 70.30 55.90 7.20 2.30 32.80 1.90 
  San Jose 1067 69.40 82.40 15.30 ǂ ǂ ǂ 
  Los Angeles 4264 61.00 78.50 15.30 2.60 3.20 0.40 
  Greater 
California 
10681 68.90 81.50 10.50 2.10 4.40 1.40 
  Kentucky 3682 58.70 72.10 7.80 6.70 ǂ ǂ 
  Louisiana 3077 68.80 71.50 13.60 8.20 ǂ ǂ 
  New Jersey 6433 62.40 63.20 15.20 7.00 ǂ ǂ 
 
ǂCell not shown due to small numbers, per SEER-Medicare reporting rules 
*Chi-square p-value <0.0001 
 
(Continued on next page) 
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Table 11 (continued). Characteristics of Medicare lung, breast, colorectal and 
pancreatic cancer decedents and location of death among hospice users, 2007-2008  
    Total    Hospice 
users 
Location of death 
Home Nursing Home Hospital Hospice Other 
  Total 46044 30,534 21,412 4,049 1,960 2,830 283 
   %   66.30 70.10 13.30 6.40 9.30 0.90 
HMO* HMO 13251 72.10 76.40 11.30 3.80 7.60 0.90 





Breast 4737 68.70 65.90 18.00 5.40 9.30 1.40 
Colorectal 8837 66.50 68.30 15.90 6.00 8.90 0.80 
Lung 22739 64.70 71.50 11.50 6.80 9.40 0.80 
  Pancreas 4656 71.60 73.60 9.00 6.80 9.60 1.10 




Married 22319 66.00 74.20 9.00 6.50 9.40 0.80 
Never Married 3722 60.00 60.40 22.00 6.90 9.60 1.10 
  Previously 
 
17928 68.00 67.60 16.50 6.10 8.90 1.00 






Q1 10895 61.40 69.20 15.20 6.30 8.60 0.80 
Q2 10943 65.50 70.30 13.90 6.50 8.20 1.00 
Q3  10977 67.70 70.10 12.80 6.50 9.60 1.00 
Q4 11015 70.60 71.10 11.30 6.40 10.40 0.80 
  Unknown 2214 66.40 68.60 14.10 5.70 10.30 1.30 
*Chi-square p-value <0.0001 
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Table 12. Multivariate logisitic regression analysis results of predicting the 
association of patient characteristics with use of hospice at death and home death 
given use of hospice among Medicare beneficiaries who died of lung, colorectal, 
pancreatic, prostate and breast cancer, 2007-2008. 
 
 

























70-74 1.17 (1.09, 1.27)   0.9 (0.81, 1.01)   
75-79 1.29 (1.2, 1.39)   0.89 (0.8, 0.99)   
80-84 1.43 (1.33, 1.55)   0.86 (0.77, 0.95)   
85+ 1.56 (1.45, 1.69)   0.79 (0.71, 0.88)   





Male 0.74 (0.7, 0.77)   0.96 (0.9, 1.02)   





Black 0.7 (0.65, 0.75)   0.88 (0.8, 0.97)   
Hispanic 1 (0.91, 1.09)   1.23 (1.09, 1.39)   
Asian/PI 0.62 (0.56, 0.68)   0.99 (0.85, 1.17)   





San Francisco 0.34 (0.29, 0.39)   10.96 (9.09, 13.2)   
Connecticut 0.38 (0.33, 0.43)   1.88 (1.63, 2.17)   
Detroit 0.56 (0.48, 0.64)   2.89 (2.49, 3.36)   
Hawaii 0.38 (0.32, 0.47)   2.91 (2.25, 3.75)   
New Mexico 0.62 (0.52, 0.73)   3.64 (3, 4.41)   
Seattle 0.41 (0.36, 0.47)   5.04 (4.32, 5.87)   
Utah 0.91 (0.75, 1.12)   6.6 (5.28, 8.26)   
Atlanta 0.57 (0.48, 0.67)   2.75 (2.29, 3.3)   
San Jose 0.46 (0.38, 0.54)   9.26 (7.41, 11.57)   
Los Angeles 0.31 (0.27, 0.35)   7.64 (6.53, 8.94)   
Greater California 0.45 (0.4, 0.51)   7.88 (6.95, 8.93)   
Kentucky 0.4 (0.36, 0.45)   3.98 (3.48, 4.54)   
Louisiana 0.6 (0.53, 0.68)   4.04 (3.53, 4.63)   
New Jersey 0.36 (0.32, 0.41)   3.67 (3.21, 4.21)   
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Table 12 (continued). Multivariate logisitic regression analysis results of predicting 
the association of patient characteristics with use of hospice at death and home 
death given use of hospice among Medicare beneficiaries who died of lung, 
colorectal, pancreatic, prostate and breast cancer, 2007-2008. 
 
 



















Big Metro 1.5 (1.26, 1.79) <0.0001 0.61 (0.48, 0.77) <0.0001 
 Metro 1.43 (1.2, 1.7)   0.83 (0.66, 1.04)   
Urban 1.07 (0.89, 1.29)   1.23 (0.96, 1.58)   
Less Urban 0.96 (0.8, 1.14)   1.05 (0.83, 1.33)   
Rural 1 
 
  1 
 
  
















 Breast 0.87 (0.79, 0.96)   0.94 (0.83, 1.06)   
Colorectal 0.93 (0.86, 1.01)   1.03 (0.93, 1.14)   
Lung 0.92 (0.86, 0.99)   1.17 (1.07, 1.29)   

















Never Married 0.83 (0.78, 0.9) 0.52 (0.47, 0.57) 
Previously Married 0.98 (0.94, 1.03) 0.73 (0.69, 0.78) 
Unknown 0.98 (0.89, 1.08) 0.72 (0.64, 0.82) 
 
   67 
Figure 5. Length of stay in hospice by location of death among Medicare hospice 
users who died of lung, prostate, breast, colorectal and pancreatic cancer, 2007-
2008. 
 
Table 13. Logistic regression analysis* predicting inappropriate length of stay (<7 



















Home  1 
  
<0.0001  1 
  
<0.0001 
 Nursing Home 1.137 (1.056, 1.224)   1.506 (1.301, 1.743)   
Hospital 4.307 (3.884, 4.775)   0.408 (0.281, 0.955)   
Hospice 1.56 (1.434, 1.698)   0.761 (0.646, 1.315)   
Other 1.205 (0.943, 1.54)   0.646 (0.38, 0.802)   
*Multivariate model including registry, age, sex, race, HMO vs. FFS, urban/rural status, 
marital status and zip code median income. 
 
   68 
Conclusion 
 
The Medicare Hospice Benefit (MHB) was introduced to provide an alternative to 
the increasingly aggressive and institutionalized care at the end of life.  The scope of the 
MHB was tightly circumscribed to provide non-institutional care for up to six months 
prior to death for patients who desired care that acknowledged the fact that they were 
dying.112  The three papers above challenge common assumptions about how the MHB is 
used.  The first analysis describes the disparity in hospice use between blacks and non-
Hispanic whites over time.  We find that although the disparity remains throughout our 
observation period, our ability to explain the disparity has decreased over time.  The 
second analysis finds that lung cancer patients who use no treatment or one treatment use 
hospice at the same rate as patients who use very aggressive care (3 or more treatments), 
while patients who use less aggressive care use significantly less.  The final analysis 
describes the place of death among MHB users with cancer.  Almost one-third of patients 
died in institutional settings.  Those who died in institutional settings had less optimal 
length of hospice stay than those who died at home.   
With greatly increased use of hospice in the last two decades, the profile of 
hospice and hospice users has also changed. Hospice use increased over time, but the 
proportion of hospice users with optimal lengths of stay decreased.  34,113,114 The increase 
in use, however, does not mean that barriers to accessing hospice no longer exist.  When 
we unpack the well-established fact that blacks use hospice less often than whites, we 
find that this disparity has remained unchanged over time.  In fact, in recent years 
 
   69 
differences in demographic and clinical characteristics between these groups explain less 
of the difference in use between blacks and whites. 
The MHB requires cessation of curative treatment or treatment aimed at life 
extension because users cannot access Medicare payment for these treatments while 
using the MHB.  While this may seem to imply that patients who use hospice prior to 
death forgo treatment in order to do so, we instead find that patients that use aggressive 
treatment are just as likely to use hospice as patients who use no treatment.  Investigating 
treatment patterns from diagnosis to death allows us to determine the relationship 
between cancer care and hospice care. 
Finally, the MHB is designed for most of the care to be provided in non-
institutional homelike settings, so for many, “hospice” means “home.”  We find, 
however, that a third of the patients who died from the some of the most common cancers 
did not die at home.  Payments from the MHB do not take into account location of care 
despite the fact that patients who die in hospitals and nursing homes have access to 
formal caregivers and services.  The recent addition of a field on the billing statement to 
indicate location of care is an important step in understanding how and where the benefit 
is being used. 
 As the MHB faces challenges associated with regulatory barriers to enrollment 
and increased use by non-traditional users, the payment structure is under review.  
Empirical studies will be necessary to inform possible solutions.  The findings from the 
three analyses in this thesis may help to guide this discussion. 
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Policy implications 
In each of these analyses, we find that many patients are using the benefit in 
suboptimal ways that are challenging given the benefit’s payment design.  Patients with 
very long stays in hospice (greater than 180 days) are expensive for the Medicare 
program because the hospice collects payment for each day of enrollment.  While some 
patients defy prognostic expectations, there is concern that there is a financial incentive 
for the hospice to enroll these patients too early.  Patients who survive for longer than 
180 days may have received a benefit from treatment aimed at their terminal condition or 
from rehabilitative care that is not the specialty of hospice providers.45  Patients with very 
short lengths of stays (less than 7 days) present a challenge to hospice because newly 
admitted and actively dying patients consume large amounts of resources and there are no 
periods with relatively little resource use during which to recoup the cost.  There may be 
financial incentives for hospitals or other care providers to enroll patients who are 
imminently dying in hospice.  It is also possible that there is a cultural and/or 
administrative shift among medical providers that hospice is where you “send” patients 
who are dying, and the recognition of and acceptance of death comes late in many cases.  
One week is not enough time for patients to receive adequate physical, psychosocial and 
spiritual care provided by hospice.45 Patients who receive more aggressive treatment 
experience shorter lengths of stay than patients who receive no cancer-directed treatment.  
Patients dying in institutional locations are more likely than those who die at home to 
have a length of hospice enrollment that is very short or very long. 
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The MHB was designed with a particular patient in mind—a patient who receives 
a diagnosis of an illness that is likely terminal and wants to opt out of traditional 
medicine and dying within an institution and receive optimal care along the way.  For this 
patient, the benefit is well designed.  The large increases in hospice use may provide the 
sense that this benefit is in high demand and accessed by those who desire it.  The 
increase in the number of hospices has been said to demonstrate the sufficiency of the 
payment rates. 
The day a person will die is unknowable, making the optimal time to enroll in 
hospice difficult to ascertain.9  Physicians may find it difficult to determine and/or 
communicate an accurate prognosis, and patients may choose not to hear it.  This may 
result in delaying hospice entry until death is imminent.  Increases in very short stays 
over time suggest that this may be a systemic problem.   
These very short visits place a strain on hospices due to the capitated payment 
system.  A person newly admitted to hospice and a person near death generally require 
more hospice resources so when a person is admitted to hospice for less than three days, 
there is no chance to recoup those increased costs with payments for days that require 
fewer resources.  
The payment could be reformed to better accommodate patients with very short or 
very long stays, a proposal that has been studied and recommended by the Medicare 
Payment Advisory Commission.115 They have described the u-shaped costs of caring for 
a hospice patient, with higher costs upon admission as the providers learn about the 
patient and family and begin to treat their symptoms and higher costs in the last days of 
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care, when the patient is actively dying. Under the proposed payment reform, payments 
would be higher on days closer to admission and death.  Increasing payments for these 
stays will likely increase the proportion of very short stays as there would be greater 
incentive.  Given that hospice care received under this scenario looks different than 
hospice care for longer lengths of stay, another option may be to consider these to be 
different services altogether—“acute” vs. “chronic” care of the dying. Actively dying 
patients could be offered something that is not called hospice; perhaps in the inpatient 
setting, an end-of-life stay modifier might enable hospitals to provide inpatient 
specialized services to dying patients.116   
The findings in our final analysis highlight some reasons to make this change.  
Almost two thirds of patients who die in the hospital inpatient setting are enrolled in 
hospice for one week or less, and almost half who die in the hospital are enrolled for 
three days or fewer.  Concerns have arisen about hospitals effectively receiving dual 
payment (receiving the full diagnosis related grouping (DRG payment) plus a hospice 
payment) for this enrollment.108  Hospitals may have financial incentives to discharge 
patients to hospice, especially if the hospice is operated under the auspices of the same 
parent organization and perhaps in the same building.  In these cases, the hospital to 
hospice transition is more bookkeeping than care.  While there would be a need for tight 
oversight to ensure that hospitals were billing appropriately, changing the payment 
instead to reimburse for an end of life hospital stay would provide flexibility for the 
hospital to provide end of life care or contract with another organization to provide it. 
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Open access hospice is another policy proposal that is frequently discussed.97  In 
this model, hospice care remains the same, providing symptom management and 
psychosocial care, but providers can also be reimbursed for treatments aimed at 
managing the terminal condition.  For example, a patient may receive chemotherapy to 
shrink a tumor while enrolled in hospice.  There are many possible benefits: this would 
remove the barrier to hospice to those who wish to receive more curative or life 
extending treatment, or are simply unwilling to admit that there are no other curative 
options.  This could also reduce the number of short stays in hospice because people will 
not have to wait to “complete” treatments in order to enroll, and this would help remove 
the barrier for expensive treatments such as chemotherapy or radiotherapy which are 
primarily aimed at reducing suffering but may also extend life. Currently, while hospices 
may provide such treatment if it is deemed palliative, capitated payments prevent all but 
the largest hospices from doing so.117 If the goal is for more people to access the 
expertise of end of life specialists, this may help to further that goal.  The goal of cost 
savings as a result of hospice enrollment is less clear cut.  We found that many patients 
enrolled in hospice after receiving treatments, so there may be no difference in costs of 
treatments for the terminal condition, and there is the potential for cost savings by 
reducing the number of health care encounters for crises of symptom management or 
psychological distress.  However, the cost of hospice would increase if patients enrolled 
earlier, and the current issue faced by those who receive hospice care in hospitals and 
nursing homes, duplication of services, would be increased. 
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Finally, whether the model is open access hospice or simply patients receiving 
care from a non-hospice palliative care program, the goals of care become murkier.  
While patients who are not forced to choose between curative and palliative may more 
easily come to a realization that they will die soon and plan accordingly, it is likely that it 
would, in fact, be more difficult.  One of the most profound intangible benefits is the 
chance for patients and their families to take the actions they want to be able to take 
before they die.22  If the goal is to increase this benefit for patients and their families, it 
must start with the acknowledgement of medical care limitations and clear 
communication of those limitations by all providers. Simply discussing the hospice 
option may increase awareness.85 One single institution study found that of over half of 
patients who died in their hospital were hospice eligible according to guidelines 
published by the National Hospice and Palliative Care Organization (NHPCO), yet only 
10% of these patients were offered hospice prior to the terminal hospitalization.26  
Particularly for blacks, increased knowledge about the hospice option may increase 
use.35,118 
While the disparity in use for black patients remains unchanged, our ability to 
explain the difference using other demographic differences has decreased.  The literature 
suggests that blacks are more likely to prefer dying in a hospital versus at home, and to 
prefer aggressive treatment to hospice care.32,70,86,119 Despite these preferences, in our 
analysis, black patients were less likely to receive very aggressive treatment than other 
racial groups.  We also found that patients using only one or two treatments were less 
likely to use hospice than those using no treatments or 3 or more treatments.  Is it any 
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wonder that a patient who hasn’t been offered the full range of treatment is less likely to 
give up the opportunity to receive more?  Perhaps, counterintuitively, interventions to 
improve access to hospice for minorities are better directed at interventions to improve 
access to curative treatments at diagnosis, particularly for African Americans.   
Another strategy to improve access for blacks is to continue expanding the 
choices for hospice care.  A subgroup investigation in our final analysis reveals that 
although black hospice users are more likely to die the in the hospital than any other 
group, they are the least likely among users dying in the hospital to experience a very 
short length of stay.  For this group, enrolling in hospice within a hospital seems to be 
more intentional than other groups and probably does signal a preference to receive end 
of life care in a hospital or lack of caregiver in the home,35,105 rather than a transition in 
billing from hospital to hospice when death appears to be imminent.  Improving end of 
life care within hospitals may help this population as well with the additional caveat that 
quality of care must be monitored. 
The calls for improved communication between physicians and patients at the end 
of life, improved non-hospice medical care, and improved inpatient end of life care8,120 
are not new or controversial and they are also difficult to implement.121  Hospice payment 
reform is more easily implemented but the goal must be clear and the incentives need to 
be carefully thought out.  Our data have shown that hospice payment policy has achieved 
the goal of increased the number of hospice users and the number of hospices, but it has 
not reached all populations and does not serve all users well. 
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Facing mortality or the death of a loved one is difficult; the health care system 
should not add to the difficulty by delivering unwanted care or inadequate symptom 
management and support.  The MHB has served millions of users and is associated with 
patient satisfaction and improved outcomes for bereaved caregivers.  Our analyses have 
peered into the MHB black box to illuminate the continued racial disparity in hospice 
use, the relationship between curative treatment and hospice use, and where hospice users 
die.  We examined how cancer patients, for whom the benefit was originally designed, 
use the MHB.  To know that even these patients are using the benefit in ways that differ 
from what was originally intended will inform the discussion of the future of the 
Medicare to insure excellent end of life care is delivered to all patients near death. 
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Appendix A: Additional data and analyses for Paper 1 
 




148,935 Black and white lung, 
pancreatic and advanced gastric 
cancer patients diagnosed 
between 1992 and 2007 in 12 
  
6,564 (4%) diagnosed in nursing 
home, autopsy, death certificate 
 
8,896 (6%) Died after 2008 
 
794 (0.5%) diagnosis month 
unknown 
548 entered hospice prior to 
observation period 
117 425 elderly cancer decedents 
with A and B claims 
4,766 (4%) not enrolled in 
Medicare A and B from diagnosis 
  
 
Final cohort of 99,090 cases 
with complete variable set 
15,256 (11.5%) younger than 65 
 
389 entered hospice prior to 
diagnosis 
27 <0.1% death date inaccurate 
(died prior to hospice entry) 
 
12,605 (11.3%) Cause of 
death other than cancer 
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Table A1. Coefficients from "whites only" regression predicting hospice use prior to 
death for the first and last time periods, used to calculate Peters-Belson estimate. 
 
 
1992-1995   2004-2008   
 Coefficient Se p Coefficient Se p 
Intercept -0.2337 0.1341 0.0813 0.7467 0.1998 0.0002 
Income Q2 vs Q1 0.2269 0.0759 0.0028 0.0178 0.1267 0.888 
Income Q2 vs Q1 0.3951 0.0863 <.0001 0.1814 0.1381 0.1889 
Income Q2 vs Q1 0.3336 0.1006 0.0009 0.3902 0.1535 0.011 
Education Q2 vs Q1 -0.2655 0.0746 0.0004 0.0562 0.1202 0.6401 
Education Q2 vs Q1 -0.1908 0.0833 0.022 -0.0876 0.1293 0.4979 
Education Q2 vs Q1 -0.1619 0.0949 0.0879 -0.1428 0.1455 0.3265 
Detroit vs other registries 0.7955 0.0758 <.0001 0.5247 0.1067 <.0001 
Atlanta/Rural Georgia vs 
other registries 0.3155 0.093 0.0007 0.6255 0.1286 <.0001 
Louisiana vs other 
registries -0.0456 0.0759 0.5478 -0.1476 0.1131 0.1918 
Males vs female -0.2774 0.0497 <.0001 -0.4153 0.0719 <.0001 
Never married vs married -0.2249 0.0954 0.0184 -0.1877 0.1264 0.1376 
Separated vs married -0.0684 0.053 0.197 0.0362 0.0792 0.6478 
Unknown marital status vs 
married -0.1058 0.1901 0.5779 -0.0671 0.1839 0.715 
Lung vs pancreatic cancer -0.2271 0.0623 0.0003 -0.4156 0.0957 <.0001 
Gastric vs pancreatic 
cancer -0.2872 0.0997 0.004 -0.5138 0.1598 0.0013 
Survival 0-1 month vs 
12+ months -1.1452 0.0745 <.0001 -0.6391 0.0949 <.0001 
Survival 2-6 month vs 
12+ months -0.3405 0.0672 <.0001 -0.2753 0.0895 0.0021 
Survival 6-12 month vs 
12+ months -0.1192 0.0779 0.1259 -0.0512 0.1118 0.6471 
Regional vs localized 
disease -0.3123 0.0564 <.0001 -0.374 0.0806 <.0001 
Unknown vs localized 
disease -0.0841 0.0715 0.2391 -0.1025 0.1397 0.4632 
Age 70-74 vs 65-69 0.1199 0.064 0.0613 0.2507 0.108 0.0202 
Age 75-79 vs 65-69 0.2031 0.0674 0.0026 0.3182 0.1069 0.0029 
Age 80-84 vs 65-69 0.39 0.0759 <.0001 0.4691 0.1136 <.0001 
Age 85+  vs 65-69 0.2891 0.0893 0.0012 0.6064 0.1255 <.0001 
Rural vs non-rural -0.2379 0.8862 0.7883 -1.0282 0.9329 0.2704 
HMO vs FFS 1.1357 0.0712 <.0001 0.5862 0.0878 <.0001 
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Sensitivity Analyses 
In addition to the results presented in the text, we performed several sensitivity 
analyses to assess the robustness of our results. We performed additional analyses to 
ensure that our conclusions were not sensitive to the choice of years or the exclusion of 
registries without adequate representation of all groups of interest. Results are presented 
below. 
 
Table A2. Peters Belson estimates of the disparity in hospice use between black and 
non-Hispanic white pancreatic, lung and gastric cancer decedents (limted to 
registries where blacks comprise at least 5% of cancer patients—San Francisco, 
Detroit, Atlanta, Rural Georgia, Los Angeles (Atlanta and rural Geogria were 
grouped in the model because of small numbers from the Rural Georgia registry) 
 
1992-1995 1996-1999 2000-2003 2004-2008 
Hospice Use     
Whites 40.5% 52.0% 60.6% 67.0% 
Blacks unadjusted 31.3% 42.7% 51.3% 57.8% 
Blacks predicted 35.3% 45.3% 55.7% 60.8% 
Unadjusted disparity 9.2% 9.3% 9.3% 9.2% 










 Quality Hospice Use     
Whites 26.5% 32.9% 36.3% 37.8% 
Blacks unadjusted 20.9% 28.2% 31.7% 35.4% 
Blacks predicted 23.6% 30.4% 34.4% 36.5% 
Unadjusted disparity 5.6% 4.6% 4.5% 2.4% 
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Table A3. Peters Belson estimates of the disparity in hospice use between black and 













Hospice Use      
Whites 38.2% 48.4% 55.9% 60.7% 66.3% 
Blacks unadjusted 32.8% 41.3% 48.5% 53.3% 57.4% 
Blacks predicted 32.2% 41.5% 49.9% 54.9% 61.7% 
Unadjusted disparity 5.3% 7.1% 7.4% 7.4% 8.8% 












 Quality Hospice Use    
  
Whites 26.3% 32.5% 36.4% 38.1% 40.5% 
Blacks unadjusted 21.4% 27.8% 31.5% 32.2% 36.1% 
Blacks predicted 25.1% 30.1% 35.1% 35.4% 41.8% 
Unadjusted disparity 4.9% 4.8% 4.9% 5.9% 4.4% 
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Table A3. Multiple logistic regression estimates predicting hospice use, by time 
period 
  1992-1995 1996-1999 2000-2003 2004-2008 
  OR p-value OR p-value OR p-value OR 
p-
value      
Race     
NH-White 1.0  0.0014 1.0  0.0194 1.0  0.0605 1.0  0.1941     Black 0.808  0.876   0.905  0.936       Median Income     
Q1 1.0  0.0202 1.0  0.0366 1.0  0.0018 1.0  0.151     Q2 1.062  1.083   1.023  1.007       Q3 1.015  1.133   1.149  1.034       Q4 1.184  1.163   1.177  1.109       Education     
Q1 1.0  0.4171 1.0  0.9133 1.0  0.427 1.0  0.478     Q2 0.977  1.02   0.95  1.043       Q3 1.026  1.031   0.969  1.07       Q4 1.077  1.036   0.925  1.039       Age at death     
65-69 1.0  <0.0001 1.0  <0.0001 1.0  <0.0001 1.0  <0.0001     70-74 1.133  1.109   1.198  1.178       75-79 1.13  1.134   1.33  1.342       80-84 1.338  1.214   1.557  1.546       85+ 1.114  1.276   1.659  1.711       Registry     
San 






1.0  <0.0001     
Atlanta 1.18  1.181   1.26  1.171       Connecticut 0.858  0.726   0.785  0.726       Detroit 1.556  1.191   1.156  0.866       Atlanta 0.864  1.237   1.663  1.234       Hawaii 0.656  0.98   0.986  0.818       Iowa 1.401  1.554   1.656  1.584       Los Angeles 0.849  0.754   0.88  0.737       New Mexico 1.29  1.376   1.503  1.339       San Jose 1.043  0.996   0.994  0.892       Seattle 1.136  1.103   1.143  0.988       Utah 0.482  1.146   1.683  1.449       Sex     
Female 1.0  <0.0001 1.0  <0.0001 1.0  <0.0001 1.0  <0.0001     Male 0.81  0.806   0.743  0.754       
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Table A3 (continued). Multiple logistic regression estimates predicting hospice use, 
by time period 
  1992-1995 1996-1999  2000-2003 2004-2008     
  OR p-value OR p-value   OR 
p-
value OR     
Marital Status     
Never 








    
Married 1.207 
 
1.02   1.17  1.11       Previously 
Married 
1.148 1.109   1.182  1.149 
      
Unknown 1.023  0.955   1.038  1.205       Payment     
FFS 1.0  <0.0001 1.0  <0.0001 1.0  <0.0001 1.0  <0.0001     HMO 2.199  1.622   1.454  1.401       Stage     
Regional 1.0  0.0016 1.0  <0.0001 1.0  0.0002 1.0  <0.0001     Distant 1.162  1.17   1.135  1.157       Unknown 1.12  1.218   1.162  1.269       Survival     
0-1 month 1.0  <0.0001 1.0  <0.0001 1.0  <0.0001 1.0  <0.0001     2-6 months 0.282  0.3   0.345  0.363       7-12 
months 
0.907  1.018   1.112  1.164 
      
12+ 
months 
0.897  0.973   1.068  1.027 
      
Cancer Type     
Lung 1.0  <0.0001 1.0  <0.0001 1.0  <0.0001 1.0  <0.0001     Gastric 1.084  1.234   1.129  1.17       Pancreatic 1.345   1.345   1.467   1.468        
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Appendix B: Additional data and analyses for Paper 2 
 




16,578 elderly (66+) diagnosed with 
AJCC Stage III lung cancer between 
2000 and 2006 
52 diagnosed in nursing home, 
autopsy, death certificate  19 month of diagnosis 
unknown 
 1,655 Not enrolled in A and B at 
least 12 months prior to treatment 
 
 
 13 Enrolled in hospice prior to 
lung cancer or had non lung cancer 
diagnosis 
9,413 with  
complete claims 
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Sensitivity analyses 
The patient’s date of death in Medicare does not always match the final discharge date in 
hospice for a few reasons:  the patient may be discharged from hospice alive, the date of 
death recorded by Medicare may be incorrect (in some cases, it is recorded simply as the 
final day of the month of death),1 or the date of discharge recorded by the hospice may be 
inaccurate.  For 297 hospice users, the date of death did not match the discharge date 
from hospice.  For 129 patients (46.9%), the date of death was within one week.  For an 
additional 95 (34.5%) patients, the date of death was between 8 and 30 days different.  
Our analysis reports hospice length of stay, so inaccuracies may change our results.  To 
assess this possibility, the analysis was run again excluding patients for whom the dates 
did not match. 
   
The results that follow report our findings with these patients excluded. 
 
Table B1. Codes used to identify treatments 




32440, 32442, 32445, 
32480, 32482, 32484, 
32486, 32488, 32500, 
32503, 32520, 32522, 
32525, 32657, 32663 














77418, 0073T, G0174, 
77421, 77402-77416, 
77520-77525, G0173, 
G0242, G0243, G0251, 
G0338, G0339, G0340, 
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Table B2. Unadjusted frequency of hospice use by number of treatments 
  Treatments p-value 
   0 1 2 3   
Total   2279 2282 2072 2492  
% who died before 2008 81.8% 77.7% 75.8% 67.0%  
Hospice use among those who died 54.7% 56.0% 52.7% 56.2% 0.1677  
 
Table B3. Logistic regression model predicting hospice use* 





Treatments 0 0.883 0.766 1.018 0.1434 
  1 0.918 0.796 1.06  
  2 0.846 0.734 0.976  
  3 1.0 (ref) 
  
 
*Covariates included in the model were: age, sex, race, registry, marital status, zip code 
income and education, stage( IIIa vs. IIIb),  Charlson comorbidity score. 
 
Table B4. Cox proportional hazards model predicting cancer specific mortality and 
time to hospice entry 
  Cancer specific mortality  Time to hospice 













Treatments 0 3.78 3.452 4.14 <.0001 3.359 3.131 3.603 <.0001 
  1 1.853 1.692 2.029 <.0001 1.917 1.787 2.057 <.0001 
  2 1.473 1.345 1.613 <.0001 1.541 1.437 1.652 <.0001 





(ref)    
 
Table B5. Cox proportional hazards model predicting survival after hospice entry 
  Cancer specific mortality  






Treatments 0 0.779 0.709 0.857 <.0001 
  1 0.879 0.801 0.966 0.0072 
  2 0.894 0.812 0.984 0.0215 












Interval p value 
Treatments 0 3.807 (3.485,4.159) <.0001 
  1 1.862 (1.704,2.034) <.0001 
  2 1.451 (1.327,1.586) <.0001 
  3 1 (ref)   
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The high mortality rate in our cohort creates the possibility of bias in our Kaplan Meier 
estimates.  We conducted a competing risks analysis, with death included as a competing 
event, to assess the sensitivity of our results to this method. 
 
Figure B2. Competing risks analysis: unadjusted cumulative incidence of hospice 




Table B7. Multivariate* Cox Proportional Hazards model predicting time to hospice 
with death as a competing risk event 
  Cancer specific mortality  






Treatments 0 3.904 3.551 4.292 <.0001 
  1 2.143 1.95 2.355 <.0001 
  2 1.656 1.507 1.819 <.0001 
  3 1.0 (ref) 
  
 
*Covariates included in the model were: age, sex, race, registry, marital status, zip code 
income and education, stage( IIIa vs. IIIb),  Charlson comorbidity score. 
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Appendix C: Additional data and analyses for Paper 3 
 





54,865 elderly patients diagnosed with prostate, 
pancreas, colorectal, lung, breast cancer 1992-2007 
who died of their cancer in 2007 and 2008 
1,569  (2.8%) diagnosed on 
autopsy, nursing home, death 
certificate 
608 (1.1%) SEER diagnosis month 
unknown 
 
5,427 (10.0%) not enrolled in 
Medicare Parts A and B (or HMO) 
from diagnosis to death 
46,044 with complete claims 
information and variable set 
193 (0.4%) patients with other or 
unknown race 
 
1,204 (2.6%) patients discharged 
from hospice alive 
30,534 hospice users 
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Location  N Category  N 
Q5001 Home 20,594 
Home 
21,412 
Q5002 Assisted Living Facility 818 
Q5003 Non-skilled Nursing Home 1,738 
Nursing Home 
4,049 
Q5004 Skilled Nursing Facility 2,311 
Q5005 Inpatient Hospital 1,960 Inpatient Hospital 1,960 
Q5006 Inpatient  Hospice facility 2,830 Inpatient Hospice 2,830 





Q5008 Inpatient Psychiatric Facility 0 
Q5009 Not Otherwise Specified 261 
Q5010 Hospice Facility* n/a   n/a 
  Total 30,534   30,534 
*Code introduced in 2010 (after our period of study) to denote patients receiving care 
in a hospice residential facility (e.g., receiving routine home care while residing in a 
hospice facility). 
n/a--not applicable 
    
 
 
 
 
 
 
